Professor John McMurray

  • Professor of Cardiology (Cardiovascular & Metabolic Health)

telephone: 01413303479
email: John.McMurray@glasgow.ac.uk

RC217Level C2, School of Cardiovascular and Metabolic Health, BHF Glasgow CRC, Glasgow G12 8TA

Import to contacts

ORCID iDhttps://orcid.org/0000-0002-6317-3975

Biography

John McMurray OBE, BSC (Hons), MB ChB (Hons), MD, FRCP, FESC, FACC, FAHA, FRSE, FMedSci

Professor McMurray is currently Professor of Medical Cardiology and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.

Professor McMurray served as the inaugural Eugene Braunwald Scholar in Cardiovascular Disease at the Brigham and Women’s Hospital, Boston, and visiting Professor of Medicine, Harvard University, Boston, Massachusetts USA 2010/2011. He is a Past-President of the Heart Failure Association of the ESC.

He is a Highly Cited Researcher (https://recognition.webofscience.com/awards/highly-cited/2021/) and has a H-index of >200 (https://scholar.google.com/citations?user=n0ZdRMoAAAAJ&hl=en). He is and has been involved in many guideline committees, including chairing the Task Force for 2012 ESC Guidelines on heart failure and was a member of the 2016 and 2021 Task Forces. Professor McMurray is an Associate Editor for JACC-Heart Failure and is also a member of the editorial board of several journals including the European Journal of Heart Failure, Diabetes Care and the New England Journal of Medicine, and Guest Editor for Circulation & Circulation: Heart Failure. He is the Congress Programme Committee Chair for the European Society of Cardiology 2023/2024 and European Society of Cardiology Board Member.

Professor McMurray was a member of the recent European Society of Cardiology (ESC) Task Force that created a policy on gender https://www.escardio.org/static-file/Escardio/About%20the%20ESC/Documents/European%20Society%20of%20Cardiology%20Gender%20Policy.pdf  and the NEJM policy group on diversity in research studies https://www.nejm.org/doi/full/10.1056/NEJMe2114651

He has won several awards, including the Stokes Medal of the Irish Cardiac Society. In June 2015, Professor John McMurray and Professor Salim Yusuf (McMaster University, Hamilton Ontario, Canada) were jointly awarded the 8th Arrigo Recordati International Prize for Scientific Research (for outstanding contributions in secondary prevention and risk reduction strategies in patients with cardiovascular diseases).

Professor McMurray is the recipient of the Mackenzie Medal, which is awarded by the British Cardiovascular Society in recognition of outstanding service to British Cardiology. He is also the recipient of the Louis and Artur Lucian Award for Research in Circulatory Diseases, which is awarded each year by McGill University, Montreal. This international award recognises outstanding research in the field of circulatory diseases by a scientific investigator, or group of investigators, whose contribution to knowledge in this field is deemed worthy of special recognition.

Professor McMurray was awarded an (honorary) OBE in 2019 by Her Majesty the Queen, in recognition of his services to cardiovascular research. In 2020 he was awarded the Gold Medal of the European Society of Cardiology, which the society describes as “the highest honour it can bestow on exceptional scientists for their contribution to cardiovascular medicine”. In 2021 Professor McMurray received the Rigshospitalet’s International KFJ Award. In 2023 he was made an honorary fellow of the Japanese Circulation Society. Professor McMurray has been invited to lecture widely at many international congresses and delivered many several named lectures.

Research interests

Research Theme: Cardiac Diseases

Prof McMurray’s primary research interests are in heart failure and the cardiovascular consequences of diabetes and chronic kidney disease, with a focus on clinical trials.  He is, or was, the principal investigator, member of the executive committee or steering committee member for several large trials in his areas of interest including the completed CHARM-Added, CORONA, I-Preserve, EMPHASIS-HF, PARADIGM-HF, ATMOSPHERE, Harmony-Outcomes, PARAGON-HF, GALACTIC-HF, DAPA-HF, DAPA-CKD, ASCEND-D and -ND trials, DELIVER, the ongoing FINEARTS-HF trial and the recently announced FINALITY trial.

DAPA-HF trial website: www.dapatrial.org

DELIVER trial website: www.delivertrial.org

He has been a member and chair of many guideline committees and the lead author of the World Health Organization and first Scottish Intercollegiate Guidelines Network Guidelines on the Management of HF. In addition, he was a member of the 2008 ESC HF Guidelines Task Force, and Chair of the 2012 Task Force and member of the 2013 American College of Cardiology/American Heart Association HF Guidelines Committee and the 2014 National Institute for Health and Care Excellence (NICE) Acute HF Guideline Committee.

He is a member of NICE Appraisal Committee A and a member of the editorial board of the New England Journal of Medicine and sit on the editorial board of several leading cardiovascular journals, including the European Heart Journal (Associate Editor) and Circulation.

In 2013, Prof McMurray was identified as one of the 400 most influential biomedical researchers in the world and the only cardiovascular researcher on this list from the UK (Boyack KW, Klavans R, Sorensen AA, Ioannidis JP. A list of highly influential biomedical researchers,1996-2011. Eur J Clin Invest. 2013; 43:1339-65). I have also been included in the 2014, 2016, 2017 and 2018 Highly Cited Researchers listing and one of The World's Most Influential Scientific Minds: 2014 by Thomson Reuters.

  1. Boyack KW, Klavans R, Sorensen AA, Loannidis JP. A list of highly influential biomedical researchers, 1996-2011 Eur J Clin Invest 2013;43:1339-65.

Google Scholar

https://www.webofscience.com/wos/author/record/B-2467-2013 

https://research.com/scientists-rankings/best-scientists/gb 

250px

Research groups

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985
Number of items: 1552.

2024

Abdin, A. et al. (2024) Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: an analysis of DAPA-HF and DELIVER. European Journal of Heart Failure, (doi: 10.1002/ejhf.3350) (Early Online Publication)

Espersen, C. et al. (2024) Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure. International Journal of Cardiology, 406, 132036. (doi: 10.1016/j.ijcard.2024.132036) (PMID:38599465)

Conrad, N. et al. (2024) Temporal trends and patterns in cardiovascular disease incidence: a population-based study in 22 million individuals. British Medical Journal, 385, e078523. (doi: 10.1136/bmj-2023-078523) (PMID:38925788) (PMCID:PMC11203392)

Kondo, T. et al. (2024) Low natriuretic peptide levels and outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, (doi: 10.1016/j.jchf.2024.04.027) (PMID:38904646) (In Press)

Matsumoto, S. et al. (2024) Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. Journal of the American College of Cardiology, 83(24), pp. 2426-2436. (doi: 10.1016/j.jacc.2024.03.426) (PMID:38739064)

Friday, J. M. et al. (2024) Loop diuretic utilisation with or without heart failure: impact on prognosis. European Heart Journal, (doi: 10.1093/eurheartj/ehae345) (PMID:38845446) (Early Online Publication)

Chatur, S. et al. (2024) Sacubitril/valsartan in patients with heart failure and deterioration in eGFR to <30 mL/min/1.73 m2. JACC: Heart Failure, (doi: 10.1016/j.jchf.2024.03.014) (PMID:38842957) (In Press)

Chatur, S. et al. (2024) Effects of sacubitril/valsartan across the spectrum of renal impairment in patients with heart failure. Journal of the American College of Cardiology, 83(22), pp. 2148-2159. (doi: 10.1016/j.jacc.2024.03.392) (PMID:38588927)

Pabón, M. A. et al. (2024) Sex differences in heart failure with improved ejection fraction. JACC: Heart Failure, 12(6), pp. 1119-1122. (doi: 10.1016/j.jchf.2024.03.011) (PMID:38661586)

Lam, C. S.P. et al. (2024) Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3294) (PMID:38783712)

Kondo, T. et al. (2024) Dapagliflozin and days of full health lost through death, hospitalization, and impaired well-being in DAPA-HF. Journal of the American College of Cardiology, 83(20), pp. 1973-1986. (doi: 10.1016/j.jacc.2024.03.385) (PMID:38537918)

Davis, J. A., Booth, D., McEwan, P., Solomon, S. D., McMurray, J. J.V. , de Boer, R. A., Comin‐Colet, J., Bachus, E. and Chen, J. (2024) Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: a pooled analysis of DAPA-HF and DELIVER data. European Journal of Heart Failure, 26(3), pp. 664-673. (doi: 10.1002/ejhf.3197) (PMID:38509642)

Curtain, J. P. et al. (2024) Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.3290) (PMID:38741283) (Early Online Publication)

Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, (doi: 10.1002/ehf2.14830) (PMID:38715187) (Early Online Publication)

Foà, A. et al. (2024) Sacubitril/Valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction. Journal of the American College of Cardiology, 83(18), pp. 1731-1739. (doi: 10.1016/j.jacc.2024.02.035) (PMID:38537919)

McMurray, J. (2024) A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials. Nature Medicine, (doi: 10.1038/s41591-024-02941-8) (Early Online Publication)

Yang, M. et al. (2024) Dapagliflozin and quality of life measured using the EuroQol 5-Dimension questionnaire in patients with HFrEF and HFmrEF/HFpEF. European Journal of Heart Failure, (doi: 10.1002/ejhf.3263) (PMID:38700986) (Early Online Publication)

McDowell, K. et al. (2024) Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. JAMA Cardiology, 9(5), 457. (doi: 10.1001/jamacardio.2024.0284) (PMID:38536153)

Gilbert, M. P., Skelly, J., Hernandez, A. F., Green, J. B., Krychtiuk, K. A., Granger, C. B., Leiter, L. A., McMurray, J. J.V. , Del Prato, S. and Pratley, R. E. (2024) Effect of albiglutide on cardiovascular outcomes in older adults: a post hoc analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism, 26(5), pp. 1714-1722. (doi: 10.1111/dom.15479) (PMID:38317618)

Matsumoto, S. et al. (2024) Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF. European Journal of Heart Failure, 26(5), pp. 1125-1138. (doi: 10.1002/ejhf.3223) (PMID:38587090)

Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)

Butt, J. et al. (2024) Dapagliflozin and timing of prior heart failure hospitalization a patient-level meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, (doi: 10.1016/j.jchf.2024.01.018) (PMID:38573262) (In Press)

Peikert, A. et al. (2024) Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER Trial. JACC: Heart Failure, 12(4), pp. 631-644. (doi: 10.1016/j.jchf.2023.09.007) (PMID:37767674)

Peikert, A. et al. (2024) Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA-HF and DELIVER. European Journal of Heart Failure, 26(4), pp. 912-924. (doi: 10.1002/ejhf.3184) (PMID:38487939)

Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, (doi: 10.1002/ehf2.14742) (Early Online Publication)

Knigge, P. et al. (2024) Temporal trends in the initiation of dialysis among patients with heart failure with or without diabetes: a nationwide study from 2002 to 2016. Journal of the American Heart Association, 13(6), e032539. (doi: 10.1161/JAHA.123.032539) (PMID:38471834) (PMCID:PMC11009989)

Bhatt, A. S. et al. (2024) Cost effectiveness of dapagliflozin for heart failure across the spectrum of ejection fraction: an economic evaluation based on pooled, individual participant data from the DELIVER and DAPA-HF trials. Journal of the American Heart Association, 13(5), e032279. (doi: 10.1161/JAHA.123.032279) (PMID:38390793) (PMCID:PMC10944049)

Mann, D. L. et al. (2024) Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI. Journal of the American College of Cardiology, 83(9), pp. 904-914. (doi: 10.1016/j.jacc.2024.01.002) (PMID:38418004)

Adamo, M. et al. (2024) Tricuspid regurgitation and clinical outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 12(3), pp. 552-563. (doi: 10.1016/j.jchf.2023.11.018) (PMID:38300212)

Dimond, M. G. et al. (2024) Left ventricular ejection fraction and the future of heart failure phenotyping. JACC: Heart Failure, 12(3), pp. 451-460. (doi: 10.1016/j.jchf.2023.11.005) (PMID:38099892)

Butt, J. H. et al. (2024) Heart failure, investigator-reported sleep apnea and dapagliflozin: A patient-level pooled meta-analysis of DAPA-HF and DELIVER. Journal of Cardiac Failure, 30(3), pp. 436-448. (doi: 10.1016/j.cardfail.2023.08.027) (PMID:38104937)

Ferguson, L. D. , Molenberghs, G., Verbeke, G., Rahimi, K., Rao, S., McInnes, I. B. , McMurray, J. J.V. , Sattar, N. and Conrad, N. (2024) Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls. Lancet Rheumatology, 6(3), e156-e167. (doi: 10.1016/S2665-9913(23)00338-7)

Minamisawa, M. et al. (2024) Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON‐HF study. European Journal of Heart Failure, (doi: 10.1002/ejhf.3167) (PMID:38369856) (Early Online Publication)

Heerspink, H. J.L. et al. (2024) Dapagliflozin and blood pressure in patients with chronic kidney disease and albuminuria. American Heart Journal, (doi: 10.1016/j.ahj.2024.02.006) (PMID:38367893) (In Press)

Wang, X. et al. (2024) Effects of dapagliflozin in patients in Asia: a post hoc subgroup analysis from the DELIVER trial. JACC: Asia, 4(2), pp. 108-118. (doi: 10.1016/j.jacasi.2023.10.005) (PMID:38371292) (PMCID:PMC10866733)

Brum, W. S., Docherty, K. F. , Ashton, N. J., Zetterberg, H., Hansson, O., McMurray, J. J. V. and Blennow, K. (2024) Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurology, 81(2), pp. 197-200. (doi: 10.1001/jamaneurol.2023.4719) (PMID:38109077) (PMCID:PMC10728797)

Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)

Owen, R. et al. (2024) Sex differences in the clinical presentation and natural history of dilated cardiomyopathy. JACC: Heart Failure, 12(2), pp. 352-363. (doi: 10.1016/j.jchf.2023.10.009) (PMID:38032570) (PMCID:PMC10857810)

Vart, P. et al. (2024) Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 79(2), glad181. (doi: 10.1093/gerona/glad181) (PMID:37527836) (PMCID:PMC10809037)

Petrie, M. C. et al. (2024) Pulmonary congestion and left ventricular dysfunction after myocardial infarction: insights from the PARADISE-MI trial. Circulation, 149(4), pp. 335-38. (doi: 10.1161/CIRCULATIONAHA.123.066163) (PMID:38252738)

Lala, A. et al. (2024) Standardized definitions for evaluation of acute decompensated heart failure therapies. JACC: Heart Failure, 12(1), pp. 1-15. (doi: 10.1016/j.jchf.2023.09.030) (PMID:38069997)

Lee, M. M.Y. , Kondo, T., Campbell, R. T., Petrie, M. C. , Sattar, N. , Solomon, S. D., Vaduganathan, M., Jhund, P. S. and McMurray, J. J.V. (2024) Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomised controlled trials. European Heart Journal: Cardiovascular Pharmacotherapy, 10(1), pp. 68-80. (doi: 10.1093/ehjcvp/pvad067) (PMID:37740450) (PMCID:PMC10766905)

Osmanska, J. et al. (2024) A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073) (PMID:37804170) (PMCID:PMC10766906)

Monzo, L. et al. (2024) High risk of stroke in patients with worsening heart failure, reduced ejection fraction, coronary heart disease and sinus rhythm: risk prediction score analysis from the COMMANDER-HF trial. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2023.11.020) (Early Online Publication)

2023

Ostrominski, J. W. et al. (2023) Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: The DELIVER trial. Circulation, 148(24), pp. 1945-1957. (doi: 10.1161/CIRCULATIONAHA.123.065254) (PMID:37830208)

McMurray, J. J.V. et al. (2023) Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation, (doi: 10.1161/CIRCULATIONAHA.123.065061) (PMID:38059368) (Early Online Publication)

Bhatt, A. S. et al. (2023) Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal of Heart Failure, 25(12), pp. 2177-2188. (doi: 10.1002/ejhf.3043) (PMID:37771274)

Fletcher, R. A. et al. (2023) Effect of SGLT2 inhibitors on discontinuation of renin–angiotensin system blockade: A joint analysis of the CREDENCE and DAPA-CKD trials. Journal of the American Society of Nephrology, 34(12), pp. 1965-1975. (doi: 10.1681/ASN.0000000000000248) (PMID:37876229)

Kondo, T. et al. (2023) Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16(12), e010898. (doi: 10.1161/CIRCHEARTFAILURE.123.010898) (PMID:37886880)

Matsumoto, S. et al. (2023) Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25(12), pp. 2202-2214. (doi: 10.1002/ejhf.3044) (PMID:37771260)

Pabon, M. et al. (2023) Sex differences in heart failure with reduced ejection fraction in the GALACTIC-HF trial. JACC: Heart Failure, 11(12), pp. 1729-1738. (doi: 10.1016/j.jchf.2023.07.029) (PMID:37831045)

Vardeny, O. et al. (2023) Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine, 29(12), p. 3269. (doi: 10.1038/s41591-023-02302-x) (PMID:36932245)

Zahir Anjum, D. et al. (2023) Initiation of medical therapy for heart failure patients according to kidney function: a Danish nationwide study. Clinical Epidemiology, 15, pp. 855-866. (doi: 10.2147/clep.s412787) (PMID:37489222) (PMCID:PMC10363354)

Chatur, S. et al. (2023) Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. Circulation, 148(22), pp. 1735-1745. (doi: 10.1161/circulationaha.123.066506) (PMID:37632455) (PMCID:PMC10664793)

Matsumoto, S. et al. (2023) Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry. Journal of Cardiology, (doi: 10.1016/j.jjcc.2023.11.005) (PMID:38000538) (In Press)

Pellicori, P. et al. (2023) Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS‐986231). European Journal of Heart Failure, (doi: 10.1002/ejhf.3077) (PMID:37990754) (Early Online Publication)

Mc Causland, F. R. et al. (2023) Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiology, 9(2), pp. 144-152. (doi: 10.1001/jamacardio.2023.4664) (PMID:37952176)

McDowell, K., Adamson, C., Jackson, C., Campbell, R., Welsh, P. , Petrie, M. C. , McMurray, J. J.V. , Jhund, P. and Herring, N. (2023) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, (doi: 10.1002/ejhf.3085) (PMID:37937329) (Early Online Publication)

Chatur, S. et al. (2023) Dapagliflozin in patients with heart failure and deterioration in renal function. Journal of the American College of Cardiology, 82(19), pp. 1854-1863. (doi: 10.1016/j.jacc.2023.08.026) (PMID:37634707)

Leong, D. P. et al. (2023) Frailty and outcomes in heart failure patients from high-, middle-, and low-income countries. European Heart Journal, 44(42), pp. 4435-4444. (doi: 10.1093/eurheartj/ehad595) (PMID:37639487) (PMCID:PMC10635666)

Ostrominski, J. W. et al. (2023) Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC: Heart Failure, 11(11), pp. 1491-1503. (doi: 10.1016/j.jchf.2023.05.015) (PMID:37226448)

Schou, M. et al. (2023) Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3079) (PMID:37933184) (Early Online Publication)

Byrne, R. A. et al. (2023) 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. European Heart Journal, 44(41), pp. 4310-4320. (doi: 10.1093/eurheartj/ehad476) (PMID:37632756)

Bhatt, A. S. et al. (2023) Health and economic evaluation of sacubitril-valsartan for heart failure management. JAMA Cardiology, 8(11), pp. 1041-1048. (doi: 10.1001/jamacardio.2023.3216) (PMID:37755814)

Butt, J. H. et al. (2023) Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER. European Journal of Heart Failure, 25(11), pp. 2078-2090. (doi: 10.1002/ejhf.3000) (PMID:37634087)

Heerspink, H. J. L. et al. (2023) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes, Obesity and Metabolism, 25(11), pp. 3327-3336. (doi: 10.1111/dom.15232) (PMID:37580309)

Kondo, T. et al. (2023) Use of win statistics to analyze outcomes in the DAPA-HF and DELIVER trials. NEJM Evidence, 2(11), (doi: 10.1056/EVIDoa2300042)

Ostrominski, J. W. et al. (2023) Duration of heart failure with preserved ejection fraction and outcomes with sacubitril/valsartan: insights from the PARAGON-HF trial. Journal of Cardiac Failure, 29(11), pp. 1494-1503. (doi: 10.1016/j.cardfail.2023.05.003) (PMID:37220823)

Jackson, A. M. et al. (2023) A 20-year population study of peripartum cardiomyopathy. European Heart Journal, (doi: 10.1093/eurheartj/ehad626) (PMID:37804234) (Early Online Publication)

McDonagh, T. A. et al. (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 44(37), pp. 3627-3639. (doi: 10.1093/eurheartj/ehad195) (PMID:37622666)

Rohde, L. E. and McMurray, J. J.V. (2023) REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed. European Heart Journal, 44(37), pp. 3652-3654. (doi: 10.1093/eurheartj/ehad488) (PMID:37525996)

Bozkurt, B., Desai, A. S., Ahmad, T., Deswal, A., Heidenreich, P. A., Ibrahim, N. E., McMurray, J. , Pinney, S. P., Vaduganathan, M. and Walsh, M. N. (2023) As we embark on a second year. JACC: Heart Failure, 11(10), pp. 1466-1469. (doi: 10.1016/j.jchf.2023.09.001) (PMID:37793737)

Butt, J. et al. (2023) Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction. JACC: Heart Failure, 11(10), pp. 1411-1423. (doi: 10.1016/j.jchf.2023.04.016) (PMID:37318419)

Lam, C. S.P., Docherty, K. F. , Ho, J. E., McMurray, J. J.V. , Myhre, P. L. and Omland, T. (2023) Recent successes in heart failure treatment. Nature Medicine, 29(10), pp. 2424-2437. (doi: 10.1038/s41591-023-02567-2) (PMID:37814060)

Malik, M. E. et al. (2023) Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longevity, 4(10), e552-e560. (doi: 10.1016/S2666-7568(23)00164-2) (PMID:37734395)

Peikert, A. et al. (2023) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status. JACC: Heart Failure, 11(10), pp. 1380-1393. (doi: 10.1016/j.jchf.2023.05.014) (PMID:37294244)

Burger, P. M. et al. (2023) Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: the LIFE-HF model. European Journal of Heart Failure, (doi: 10.1002/ejhf.3028) (Early Online Publication)

Docherty, K. F. et al. (2023) The effect of omecamtiv mecarbil in hospitalized patients as compared with outpatients with HFrEF: an analysis of GALACTIC-HF. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2023.08.020) (In Press)

Vissing, C. R. et al. (2023) Cardiac remodeling in subclinical hypertrophic cardiomyopathy: the VANISH randomized clinical trial. JAMA Cardiology, 8(11), pp. 1083-1088. (doi: 10.1001/jamacardio.2023.2808) (PMID:37672268)

Kondo, T. et al. (2023) Efficacy of dapagliflozin according to geographic location of patients with heart failure. Journal of the American College of Cardiology, 82(10), pp. 1014-1026. (doi: 10.1016/j.jacc.2023.05.056) (PMID:37610398)

Wang, X. et al. (2023) Sex differences in clinical characteristics and outcomes after myocardial infarction with low ejection fraction: insights from PARADISE‐MI. Journal of the American Heart Association, 12(17), e028942. (doi: 10.1161/JAHA.122.028942) (PMID:37609931) (PMCID:PMC10547323)

Matsumoto, S., Kondo, T., Jhund, P. S. , Campbell, R. T., Swedberg, K., van Veldhuisen, D. J., Pocock, S. J., Pitt, B., Zannad, F. and McMurray, J. J.V. (2023) Underutilization of mineralocorticoid antagonists in patients with heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 82(11), pp. 1080-1091. (doi: 10.1016/j.jacc.2023.06.021) (PMID:37642608)

Bhatt, A. S. et al. (2023) Operational challenges and mitigation measures during the COVID-19 pandemic – lessons from DELIVER. American Heart Journal, 263, pp. 133-140. (doi: 10.1016/j.ahj.2023.05.013) (PMID:37220822) (PMCID:PMC10200275)

Kondo, T. et al. (2023) Clinical characteristics and outcomes in patients with heart failure: are there thresholds and inflection points in left ventricular ejection fraction and thresholds justifying a clinical classification? Circulation, 148(9), pp. 732-749. (doi: 10.1161/CIRCULATIONAHA.122.063642) (PMID:37366061)

Pabon, M. et al. (2023) Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3001) (PMID:37632711) (Early Online Publication)

Chatur, S. et al. (2023) Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal, 44(31), pp. 2930-2943. (doi: 10.1093/eurheartj/ehad283) (PMID:37220093)

Ioannou, A. et al. (2023) Conventional heart failure therapy in cardiac ATTR amyloidosis. European Heart Journal, 44(31), pp. 2893-2907. (doi: 10.1093/eurheartj/ehad347) (PMID:37216684) (PMCID:PMC10424879)

Vaduganathan, M. et al. (2023) Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal, 44(31), pp. 2982-2993. (doi: 10.1093/eurheartj/ehad344) (PMID:37210743) (PMCID:PMC10424880)

Yang, M. et al. (2023) Stroke in patients with heart failure and reduced or preserved ejection fraction. European Heart Journal, 44(31), pp. 2998-3013. (doi: 10.1093/eurheartj/ehad338) (PMID:37358785) (PMCID:PMC10424882)

Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)

Inciardi, R. M. et al. (2023) Right ventricular function and pulmonary coupling in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 82(6), pp. 489-499. (doi: 10.1016/j.jacc.2023.05.010) (PMID:37225045)

Neves, J. S. et al. (2023) GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp. 517-525. (doi: 10.1016/j.jacc.2023.05.048) (PMID:37532422)

Foroutan, F. et al. (2023) Global comparison of readmission rates for patients with heart failure. Journal of the American College of Cardiology, 82(5), pp. 430-444. (doi: 10.1016/j.jacc.2023.05.040) (PMID:37495280)

Barat, A. et al. (2023) Clinical characteristics of HFrEF patients with rare pathogenic variants in DCM-associated genes: a subgroup analysis of the PARADIGM-HF trial. European Journal of Heart Failure, 25(8), pp. 1256-1266. (doi: 10.1002/ejhf.2886) (PMID:37191081)

Butt, J. H. et al. (2023) Geographic differences in patients with acute myocardial infarction in the PARADISE‐MI trial. European Journal of Heart Failure, 25(8), pp. 1228-1242. (doi: 10.1002/ejhf.2851) (PMID:37042062)

Byrne, R. A. et al. (2023) 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. European Journal of Cardio-Thoracic Surgery, 64(2), ezad286. (doi: 10.1093/ejcts/ezad286) (PMID:37632766)

Docherty, K. F. , Jackson, A. M., Macartney, M., Campbell, R. T., Petrie, M. C. , Pfeffer, M. A., McMurray, J. J.V. and Jhund, P. S. (2023) Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25(8), pp. 1213-1224. (doi: 10.1002/ejhf.2965) (PMID:37401485)

Heidenreich, P. A. and McMurray, J. J.V. (2023) Should beta-blockers be used in heart failure if the LVEF is not reduced? JACC: Heart Failure, 11(8), pp. 901-902. (doi: 10.1016/j.jchf.2023.05.023) (PMID:37452802)

Jankowska, E. A. et al. (2023) Optimizing outcomes in heart failure: 2022 and beyond. ESC Heart Failure, 10(4), pp. 2159-2169. (doi: 10.1002/ehf2.14363) (PMID:37060168) (PMCID:PMC10375115)

McDowell, K. et al. (2023) Incremental prognostic value of biomarkers in PARADIGM-HF. European Journal of Heart Failure, 28(8), 1406-1414-1406-1414. (doi: 10.1002/ejhf.2887) (PMID:37191207)

Monzo, L., Girerd, N., Duarte, K., Ferreira, J. P., McMurray, J. J.V. , van Veldhuisen, D. J., Swedberg, K., Pocock, S. J., Pitt, B. and Zannad, F. (2023) Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from EMPHASIS-HF trial. European Journal of Heart Failure, 25(8), pp. 1444-1449. (doi: 10.1002/ejhf.2952) (PMID:37370197)

Myhre, P. L. et al. (2023) Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan. European Journal of Heart Failure, 25(8), pp. 1396-1405. (doi: 10.1002/ejhf.2957) (PMID:37401523)

Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)

Yang, M. et al. (2023) Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2962) (PMID:37401511) (Early Online Publication)

Peikert, A. et al. (2023) Association of dapagliflozin vs placebo with individual Kansas City Cardiomyopathy Questionnaire components in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(7), pp. 684-690. (doi: 10.1001/jamacardio.2023.1342) (PMID:37208998) (PMCID:PMC10200027)

Bhatt, A. S. et al. (2023) Effect of dapagliflozin on health status and quality-of-life across the spectrum of ejection fraction: participant-level pooled analysis from the DAPA-HF & DELIVER trials. European Journal of Heart Failure, 25(7), pp. 981-988. (doi: 10.1002/ejhf.2909) (PMID:37211977)

Curtain, J. P. et al. (2023) Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11(7), pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012) (PMID:37407154)

Desai, A. S., Deswal, A., McMurray, J. J.V. , Pinney, S. P. and Vaduganathan, M. (2023) Optimizing background therapy for heart failure in clinical trials. JACC: Heart Failure, 11(7), pp. 806-809. (doi: 10.1016/j.jchf.2023.05.012) (PMID:37407155)

Kondo, T. et al. (2023) Predicting stroke in heart failure and preserved ejection fraction without atrial fibrillation. Circulation: Heart Failure, 16(7), e010377. (doi: 10.1161/CIRCHEARTFAILURE.122.010377) (PMID:37350280)

Talha, K. M. et al. (2023) Potential global impact of sodium‐glucose cotransporter‐2 inhibitors in heart failure. European Journal of Heart Failure, 25(7), pp. 999-1009. (doi: 10.1002/ejhf.2864) (PMID:37062865)

Yang, M. et al. (2023) Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2944) (PMID:37369637) (Early Online Publication)

Booth, D., Davis, J. A., McEwan, P., Solomon, S. D., McMurray, J. J.V. , de Boer, R. A., Comin‐Colet, J., Bachus, E. and Chen, J. (2023) The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health‐economic analysis of the DELIVER trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.2940) (PMID:37344985) (Early Online Publication)

Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)

Tolomeo, P. et al. (2023) Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. European Heart Journal, 44(24), pp. 2202-2212. (doi: 10.1093/eurheartj/ehad210) (PMID:37051752)

Kondo, T., Adachi, T., Koba, K., Okumura, T., Izawa, H., Murohara, T., McMurray, J. J.V. and Yamada, S. (2023) Physical frailty and use of guideline-recommended drugs in patients with heart failure and reduced ejection fraction. Journal of the American Heart Association, 12(12), e026844. (doi: 10.1161/JAHA.122.026844) (PMID:37301739) (PMCID:PMC10356033)

Sattar, N. et al. (2023) Years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study. Circulation, 147(25), pp. 1872-1886. (doi: 10.1161/CIRCULATIONAHA.122.063374) (PMID:37154040)

Desai, A. S., Lam, C. S.P., McMurray, J. J.V. and Redfield, M. M. (2023) How to manage heart failure with preserved ejection fraction: Practical guidance for clinicians. JACC: Heart Failure, 11(6), pp. 619-636. (doi: 10.1016/j.jchf.2023.03.011) (PMID:37140514)

Conrad, N. et al. (2023) Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet, 401(10391), pp. 1878-1890. (doi: 10.1016/S0140-6736(23)00457-9) (PMID:37156255)

McMurray, J. J.V. and Metra, M. (2023) Transcatheter repair of secondary mitral regurgitation. New England Journal of Medicine, 388(22), pp. 2097-2098. (doi: 10.1056/NEJMe2302924) (PMID:37256981)

Biering-Sørensen, T. et al. (2023) The effect of sacubitril/valsartan on left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). Journal of Cardiac Failure, 29(6), pp. 968-973. (doi: 10.1016/j.cardfail.2023.03.019) (PMID:37031887)

Curtain, J. P., Lee, M. M.Y. , McMurray, J. J.V. , Gardner, R. S., Petrie, M. C. and Jhund, P. S. (2023) Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart, 109(11), pp. 823-831. (doi: 10.1136/heartjnl-2022-321885) (PMID:36522146) (PMCID:PMC10314022)

Jhund, P. S. et al. (2023) Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction. A prespecified analysis of the DELIVER trial. JAMA Cardiology, 8(6), pp. 554-563. (doi: 10.1001/jamacardio.2023.0711) (PMID:37099283) (PMCID:PMC10134044)

Yeoh, S. E. et al. (2023) Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF. Circulation, 147(22), pp. 1670-1683. (doi: 10.1161/CIRCULATIONAHA.122.063327) (PMID:37039015) (PMCID:PMC10212584)

Chatur, S. et al. (2023) Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: insights from the DELIVER trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.2915) (PMID:37212168) (Early Online Publication)

Chatur, S. et al. (2023) Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.2912) (PMID:37210608) (Early Online Publication)

Clephas, P.R.D., Radhoe, S.P., Boersma, E., Gregson, J., Jhund, P.S. , Abraham, W.T., McMurray, J.J.V. , de Boer, R.A. and Brugts, J.J. (2023) Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials. European Heart Journal, (doi: 10.1093/eurheartj/ehad346) (PMID:37210750) (Early Online Publication)

Rasmussen, M. et al. (2023) Global variations in heart failure etiology, management, and outcomes. JAMA: Journal of the American Medical Association, 329(19), pp. 1650-1661. (doi: 10.1001/jama.2023.5942) (PMID:37191704) (PMCID:PMC10189564)

Chertow, G. M. et al. (2023) Effects of dapagliflozin in chronic kidney disease, with and without other cardiovascular medications: DAPA-CKD trial. Journal of the American Heart Association, 12(9), e028739. (doi: 10.1161/JAHA.122.028739) (PMID:37119064) (PMCID:PMC10227210)

Jering, K. S. et al. (2023) Prognostic importance of NT-proBNP (N-terminal pro-B-type natriuretic peptide) following high-risk myocardial infarction in the PARADISE-MI trial. Circulation: Heart Failure, (doi: 10.1161/CIRCHEARTFAILURE.122.010259) (PMID:37125529) (Early Online Publication)

Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)

Lanfear, D. E. et al. (2023) Omecamtiv mecarbil in Black patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF. JACC: Heart Failure, 11(5), pp. 569-579. (doi: 10.1016/j.jchf.2022.11.021) (PMID:36881396)

McEwan, P. et al. (2023) Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrology Dialysis Transplantation, 38(5), pp. 1260-1270. (doi: 10.1093/ndt/gfac280) (PMID:36301617) (PMCID:PMC10157747)

Chatur, S. et al. (2023) Variation in renal function following transition to sacubitril/valsartan in patients with heart failure. Journal of the American College of Cardiology, 81(15), pp. 1443-1455. (doi: 10.1016/j.jacc.2023.02.009) (PMID:36812948)

Biering-Sørensen, T. et al. (2023) Regional contributions to impaired myocardial mechanical function in heart failure with preserved ejection fraction. European Heart Journal: Cardiovascular Imaging, (doi: 10.1093/ehjci/jead062) (PMID:37039073) (Early Online Publication)

Lee, M. M. Y. and McMurray, J. J. V. (2023) Lack of benefit of renin-angiotensin system inhibitors in COVID-19. JAMA: Journal of the American Medical Association, 329(14), pp. 1155-1156. (doi: 10.1001/jama.2023.4405) (PMID:37039803)

Butt, J. H., Solomon, S. D. and McMurray, J. J.V. (2023) Response by Butt et al to letter regarding article, “Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial”. Circulation, 147(14), pp. 1119-1120. (doi: 10.1161/CIRCULATIONAHA.123.064052) (PMID:37011075)

Kondo, T. et al. (2023) Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: a prespecified analysis of the DELIVER trial. Circulation, 147(14), pp. 1067-1078. (doi: 10.1161/CIRCULATIONAHA.122.062918) (PMID:36876483)

Bruhn, J. et al. (2023) Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 44(13), pp. 1124-1132. (doi: 10.1093/eurheartj/ehac797) (PMID:36691953)

Butt, J. H. et al. (2023) Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. European Heart Journal, 44(13), pp. 1136-1153. (doi: 10.1093/eurheartj/ehad083) (PMID:36944496) (PMCID:PMC10111968)

Butt, J. H. et al. (2023) Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11(4), pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014) (PMID:36881399)

Butt, J. H. et al. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)

Conrad, N., McInnes, I. B. , Mcmurray, J. J.V. and Sattar, N. (2023) Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management? Annals of the Rheumatic Diseases, 82(4), pp. 457-459. (doi: 10.1136/ard-2022-223315) (PMID:36442979)

Dobbin, S. J.H. , Shen, L., Petrie, M. C. , Packer, M., Solomon, S. D., McMurray, J. J.V. , Lang, N. N. and Jhund, P. S. (2023) Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. European Journal of Heart Failure, 25(4), pp. 488-496. (doi: 10.1002/ejhf.2818) (PMID:36919816)

Mooney, L., Jackson, C. E., Adamson, C., McConnachie, A. , Welsh, P. , Myles, R. C. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Lang, N. N. (2023) Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circulation: Heart Failure, 16(4), e010051. (doi: 10.1161/CIRCHEARTFAILURE.122.010051) (PMID:36896709) (PMCID:PMC10101136)

Tardif, J.‐C. et al. (2023) Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Failure, 10(2), pp. 1066-1076. (doi: 10.1002/ehf2.14268) (PMID:36564955) (PMCID:PMC10053160)

Bhandari, S. et al. (2023) Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes. Journal of Nephrology, (doi: 10.1007/s40620-023-01571-6) (PMID:36995528) (PMCID:PMC10061401) (Early Online Publication)

Vaduganathan, M., Claggett, B. L., Jhund, P. , Miao, Z. M., de Boer, R. A., Lam, C. S.P., Desai, A. S., Bengsston, O., McMurray, J. J.V. and Solomon, S. D. (2023) Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 81(10), pp. 1004-1006. (doi: 10.1016/j.jacc.2022.12.026) (PMID:36889870)

Adamson, C. et al. (2023) IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11(3), pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004) (PMID:36592046)

Beernink, J. M. et al. (2023) Efficacy of dapagliflozin by baseline diabetes medications: a prespecified analysis from the DAPA-CKD study. Diabetes Care, 46(3), pp. 602-607. (doi: 10.2337/dc22-1514) (PMID:36662635)

Butt, J. H. et al. (2023) Urinary cGMP (cyclic guanosine monophosphate)/BNP (B-type natriuretic peptide) ratio, sacubitril/valsartan, and outcomes in heart failure with reduced ejection fraction: an analysis of the PARADIGM-HF trial. Circulation: Heart Failure, 16(3), pp. 247-258. (doi: 10.1161/CIRCHEARTFAILURE.122.010111) (PMID:36943907) (PMCID:PMC10022671)

Platz, E. et al. (2023) Trajectory and correlates of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction: insights from PARADISE-MI. European Heart Journal: Acute Cardiovascular Care, 12(3), pp. 155-164. (doi: 10.1093/ehjacc/zuad001) (PMID:36649251)

Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)

Wang, X. et al. (2023) Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER. Circulation, 147(8), pp. 624-634. (doi: 10.1161/CIRCULATIONAHA.122.062832) (PMID:36342789) (PMCID:PMC9974767)

Kosiborod, M. N. et al. (2023) Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction. Journal of the American College of Cardiology, 81(5), pp. 460-473. (doi: 10.1016/j.jacc.2022.11.006) (PMID:36526515)

Docherty, K. F. et al. (2023) Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B ‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure, 25(2), pp. 248-259. (doi: 10.1002/ejhf.2763) (PMID:36597719)

Johansen, N. D. et al. (2023) A composite score summarizing use and dosing of evidence-based medical therapies in heart failure: a nationwide cohort study. Circulation: Heart Failure, 16(2), e009729. (doi: 10.1161/CIRCHEARTFAILURE.122.009729) (PMID:36809039)

Kondo, T. et al. (2023) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, 3(1), pp. 122-134. (doi: 10.1016/j.jacasi.2022.10.004) (PMID:36873766) (PMCID:PMC9982290)

Malik, M. E. et al. (2023) Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes. Clinical Research in Cardiology, 112(2), pp. 215-226. (doi: 10.1007/s00392-022-02016-z) (PMID:35396632)

Miller, R. J.H., Chew, D. S., Qin, L., Fine, N. M., Chen, J., McMurray, J. J.V. , Howlett, J. G. and McEwan, P. (2023) Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure. European Journal of Heart Failure, 25(2), pp. 238-247. (doi: 10.1002/ejhf.2777) (PMID:36644849)

Rohde, L. E. et al. (2023) Associations between New York Heart Association classification, objective measures, and long-term prognosis in mild heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology, 8(2), pp. 150-158. (doi: 10.1001/jamacardio.2022.4427) (PMID:36477809)

Rawshani, A. et al. (2023) Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes. Scientific Reports, 13, 1192. (doi: 10.1038/s41598-023-27941-5) (PMID:36681691) (PMCID:PMC9867726)

Solomon, S.D., Vaduganathan, M. and McMurray, J.J.V. (2023) Dapagliflozin in heart failure with preserved ejection fraction. New England Journal of Medicine, 388(3), pp. 286-288. (doi: 10.1056/NEJMc2213974) (PMID:36652373)

Conrad, N. and McMurray, J. J.V. (2023) Cardiovascular risk in systemic autoimmune diseases – Authors' reply. Lancet, 401(10370), p. 22. (doi: 10.1016/S0140-6736(22)02426-6) (PMID:36610766) (PMCID:36041475)

Chatur, S., Claggett, B. L., Vardeny, O., Jering, K., Desai, A. S., Pfeffer, M. A., Lefkowitz, M., McMurray, J. J.V. , Solomon, S. D. and Vaduganathan, M. (2023) Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial. European Journal of Heart Failure, 25(1), pp. 87-94. (doi: 10.1002/ejhf.2703) (PMID:36181769)

Lee, M. M.Y. , Campbell, R. T., Claggett, B. L., Lewis, E. F., Docherty, K. F. , Lindner, M., Liu, J., Solomon, S. D., McMurray, J. J.V. and Platz, E. (2023) Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion. European Journal of Heart Failure, 25(1), pp. 54-60. (doi: 10.1002/ejhf.2699) (PMID:36161429) (PMCID:PMC9892176)

Mc Causland, F. R. et al. (2023) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8(1), pp. 56-65. (doi: 10.1001/jamacardio.2022.4210) (PMID:36326604)

Petrie, M. C. et al. (2023) High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 119(1), pp. 213-220. (doi: 10.1093/cvr/cvab317) (PMID:34875022) (PMCID:PMC10022850)

Sattar, N. , McMurray, J. J. V. , McInnes, I. B. , Aroda, V. R. and Lean, M. E. J. (2023) Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes and Endocrinology, 11(1), pp. 58-62. (doi: 10.1016/S2213-8587(22)00317-5) (PMID:36460014)

Schechter, M. et al. (2023) Effects of dapagliflozin on hospitalizations in patients with chronic kidney disease: a post hoc analysis of DAPA-CKD. Annals of Internal Medicine, 176(1), pp. 59-66. (doi: 10.7326/M22-2115) (PMID:36469914)

Selvaraj, S. et al. (2023) Blood pressure and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: DELIVER. JACC: Heart Failure, 11(1), pp. 76-89. (doi: 10.1016/j.jchf.2022.09.002) (PMID:36599553)

Talha, K. M., Butler, J., Greene, S. J., Aggarwal, R., Anker, S. D., Claggett, B. L., Solomon, S. D., McMurray, J. J.V. , Vaduganathan, M. and Fonarow, G. C. (2023) Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US. JAMA Cardiology, 8(1), pp. 66-73. (doi: 10.1001/jamacardio.2022.4348) (PMID:36334258)

2022

Singh, A. K. et al. (2022) Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents – post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrology Dialysis Transplantation, (doi: 10.1093/ndt/gfac342) (PMID:36565721) (Early Online Publication)

Gerstein, H. C. et al. (2022) Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: the ELIXA trial. Diabetes, Obesity and Metabolism, 25(4), pp. 1125-1129. (doi: 10.1111/dom.14954) (PMID:36546588)

Metra, M. et al. (2022) Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 43(48), pp. 5006-5016. (doi: 10.1093/eurheartj/ehac293) (PMID:35675469)

Bowman, L. et al. (2022) Randomized trials fit for the 21st century. A joint opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. European Heart Journal, 44(11), pp. 931-934. (doi: 10.1093/eurheartj/ehac633) (PMID:36525339) (PMCID:PMC10011328)

Bowman, L. et al. (2022) Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation. Circulation, 147(12), pp. 925-929. (doi: 10.1161/CIRCULATIONAHA.122.063378) (PMID:36524680)

Mehran, R. et al. (2022) The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial. Circulation, 146(23), pp. 1749-1757. (doi: 10.1161/CIRCULATIONAHA.122.060841) (PMID:36321459)

Chandra, A. et al. (2022) Health‐related quality of life outcomes in PARAGON‐HF. European Journal of Heart Failure, 24(12), pp. 2264-2274. (doi: 10.1002/ejhf.2738) (PMID:36394533)

Inzucchi, S. E. et al. (2022) Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology, 10(12), pp. 869-881. (doi: 10.1016/S2213-8587(22)00308-4) (PMID:36372069)

McEwan, P., Darlington, O., Miller, R., McMurray, J. J.V. , Wheeler, D. C., Heerspink, H. J.L., Briggs, A. , Bergenheim, K. and Garcia Sanchez, J. J. (2022) Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clinical Journal of the American Society of Nephrology, 17(12), pp. 1730-1741. (doi: 10.2215/CJN.03790322) (PMID:36323444)

Myhre, P. L. et al. (2022) Influence of NT-proBNP on efficacy of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC: Heart Failure, 10(12), pp. 902-913. (doi: 10.1016/j.jchf.2022.08.007) (PMID:36114137)

Vardeny, O. et al. (2022) Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine, 28(12), pp. 2504-2511. (doi: 10.1038/s41591-022-02102-9) (PMID:36522606) (PMCID:PMC9800271)

Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)

Vaduganathan, M. et al. (2022) Estimated event-free survival benefits with dapagliflozin in HF with mildly reduced or preserved ejection fraction. Journal of the American College of Cardiology, 80(19), pp. 1775-1784. (doi: 10.1016/j.jacc.2022.08.745) (PMID:36041669)

Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, 43(42), pp. 4469-4479. (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (PMCID:PMC9637422)

Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), pp. 4406-4417. (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (PMCID:PMC9622300)

Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, 80(18), pp. 1705-1717. (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668)

Zhang, L. et al. (2022) Aptamer proteomics for biomarker discovery in heart failure with reduced ejection fraction. Circulation, 146(13), pp. 1411-1414. (doi: 10.1161/CIRCULATIONAHA.122.061481) (PMID:36029463)

Adamson, C., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'the 50 shades of bilirubin'. Letter regarding the article 'liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF'. European Journal of Heart Failure, 24(11), pp. 2206-2207. (doi: 10.1002/ejhf.2683) (PMID:36097136)

Arulmurugananthavadivel, A. et al. (2022) Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark 1997–2017. European Heart Journal: Quality of Care and Clinical Outcomes, 8(7), pp. 750-760. (doi: 10.1093/ehjqcco/qcab073) (PMID:34625809) (PMCID:PMC9603536)

Ferreira, J. P., Pitt, B., McMurray, J. J.V. , Pocock, S. J., Solomon, S. D., Pfeffer, M. A., Zannad, F. and Rossignol, P. (2022) Steroidal MRA across the spectrum of renal function: a pooled analysis of RCTs. JACC: Heart Failure, 10(11), pp. 842-850. (doi: 10.1016/j.jchf.2022.06.010) (PMID:36328653)

Jongs, N. et al. (2022) Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. Journal of the American Society of Nephrology, 33(11), pp. 2094-2107. (doi: 10.1681/ASN.2022030306) (PMID:35977807)

Khunti, K. et al. (2022) Re-examining the widespread policy of stopping SGLT2 inhibitors during acute illness: a perspective based on the updated evidence. Diabetes, Obesity and Metabolism, 24(11), pp. 2071-2080. (doi: 10.1111/dom.14805) (PMID:35801339)

Perkovic, V. et al. (2022) The ASCEND-ND trial: study design and participant characteristics. Nephrology Dialysis Transplantation, 37(11), pp. 2157-2170. (doi: 10.1093/ndt/gfab318) (PMID:34865143) (PMCID:PMC9585467)

Smeijer, J. D. et al. (2022) Organic anion transporter gene variants associated with plasma exposure and long-term response to atrasentan in patients with diabetic kidney disease. Clinical Pharmacology and Therapeutics, 112(5), pp. 1098-1107. (doi: 10.1002/cpt.2721) (PMID:35892316)

Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61(11), pp. 4374-4383. (doi: 10.1093/rheumatology/keac072) (PMID:35136973)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation, 146(16), pp. 1210-1224. (doi: 10.1161/CIRCULATIONAHA.122.061754) (PMID:36029465) (PMCID:PMC9815819)

Tardif, J. C. et al. (2022) Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. European Heart Journal, 43(39), pp. 3947-3956. (doi: 10.1093/eurheartj/ehac374) (PMID:35856777) (PMCID:PMC9565632)

Cunningham, J. W. et al. (2022) Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. Journal of the American College of Cardiology, 80(14), pp. 1302-1310. (doi: 10.1016/j.jacc.2022.07.021) (PMID:36041912)

Garred, C. H. et al. (2022) Adherence and discontinuation of optimal heart failure therapies according to age: a Danish nationwide study. Journal of the American Heart Association, 11(19), e026187. (doi: 10.1161/JAHA.122.026187) (PMID:36172925) (PMCID:PMC9673698)

Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)

Adamson, C. et al. (2022) Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. European Journal of Heart Failure, 24(10), pp. 1856-1868. (doi: 10.1002/ejhf.2649) (PMID:36054568) (PMCID:PMC9805158)

Bedrouni, W. et al. (2022) Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction. Circulation: Heart Failure, 15(10), pp. 988-990. (doi: 10.1161/CIRCHEARTFAILURE.121.009295) (PMID:35924555)

Berwanger, O. et al. (2022) Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial. European Journal of Heart Failure, 24(10), pp. 1918-1927. (doi: 10.1002/ejhf.2663) (PMID:36054480)

Chatur, S. et al. (2022) Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with HFpEF in the PARAGON‐HF trial. European Journal of Heart Failure, 24(10), pp. 1906-1914. (doi: 10.1002/ejhf.2638) (PMID:35895867)

Claggett, B. L., McCaw, Z. R., Tian, L., McMurray, J. J.V. , Jhund, P. S. , Uno, H., Pfeffer, M. A., Solomon, S. D. and Wei, L.-J. (2022) Quantifying treatment effects in trials with multiple event-time outcomes. NEJM Evidence, 1(10), (doi: 10.1056/EVIDoa2200047)

Dubé, M.‐P. et al. (2022) Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. ESC Heart Failure, 9(5), pp. 2997-3008. (doi: 10.1002/ehf2.14026) (PMID:35736394) (PMCID:PMC9715825)

Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450) (PMCID:PMC9715817)

McDowell, K., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. European Journal of Heart Failure, 24(10), p. 1994. (doi: 10.1002/ejhf.2686) (PMID:36093864)

McMurray, J. J. V. and Sattar, N. (2022) Heart failure: now centre-stage in diabetes. Lancet Diabetes and Endocrinology, 10(10), pp. 689-691. (doi: 10.1016/S2213-8587(22)00249-2) (PMID:36057271)

Ostrominski, J. W. et al. (2022) Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Journal of Heart Failure, 24(10), pp. 1892-1901. (doi: 10.1002/ejhf.2652) (PMID:36054231)

Peikert, A. et al. (2022) Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial. Circulation: Heart Failure, 15(10), pp. 934-943. (doi: 10.1161/CIRCHEARTFAILURE.122.010080) (PMID:36029467)

Pocock, S. J. et al. (2022) Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. European Journal of Heart Failure, 24(10), pp. 1869-1878. (doi: 10.1002/ejhf.2607) (PMID:35796209)

Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)

Docherty, K. F. et al. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, 146(13), pp. 980-994. (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (PMCID:PMC9508991)

Solomon, S. D. et al. (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387(12), pp. 1089-1098. (doi: 10.1056/NEJMoa2206286) (PMID:36027570)

Butt, J. H. et al. (2022) Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 80(12), pp. 1130-1143. (doi: 10.1016/j.jacc.2022.06.037) (PMID:36050227)

Conrad, N., Verbeke, G., Molenberghs, G., Goetschalckx, L., Callender, T., Cambridge, G., Mason, J. C., Rahimi, K., McMurray, J. J.V. and Verbakel, J. Y. (2022) Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet, 400(10354), pp. 733-743. (doi: 10.1016/S0140-6736(22)01349-6) (PMID:36041475)

Vaduganathan, M. et al. (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400(10354), pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5) (PMID:36041474)

Aulin, J. et al. (2022) Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model. American Heart Journal, 251, pp. 13-24. (doi: 10.1016/j.ahj.2022.03.009) (PMID:35569564)

Butt, J. H. and McMurray, J. J.V. (2022) Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients. European Journal of Heart Failure, 24(9), pp. 1623-1624. (doi: 10.1002/ejhf.2647) (PMID:35919944)

Gerstein, H. C. et al. (2022) Protein biomarkers and cardiovascular outcomes in people with type 2 diabetes and acute coronary syndrome: the ELIXA biomarker study. Diabetes Care, 45(9), pp. 2152-2155. (doi: 10.2337/dc22-0453) (PMID:35817031)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)

Johansson, I. et al. (2022) Factors associated with health‐related quality of life in heart failure in 23,000 patients from 40 countries: results of the G‐CHF Research Program. European Journal of Heart Failure, 24(9), pp. 1478-1490. (doi: 10.1002/ejhf.2535) (PMID:35570198)

Mc Causland, F. R. et al. (2022) Angiotensin‐neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 24(9), pp. 1591-1598. (doi: 10.1002/ejhf.2421) (PMID:34989105)

Vaduganathan, M., Ferreira, J. P., Rossignol, P., Neuen, B., Claggett, B. L., Pfeffer, M. A., McMurray, J. J.V. , Pitt, B., Zannad, F. and Solomon, S. D. (2022) Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. European Journal of Heart Failure, 24(9), pp. 1586-1590. (doi: 10.1002/ejhf.2635) (PMID:35867859)

Wheeler, D. C. et al. (2022) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial. Nephrology Dialysis Transplantation, 37(9), pp. 1647-1656. (doi: 10.1093/ndt/gfab335) (PMID:34850160) (PMCID:PMC9395378)

Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)

Thomson, P. C. et al. (2022) An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. Kidney International Reports, 7(8), pp. 1793-1801. (doi: 10.1016/j.ekir.2022.05.008) (PMID:35967105) (PMCID:PMC9366296)

Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)

Smeijer, J. D. et al. (2022) Increase in BNP in response to endothelin-receptor antagonist atrasentan is associated with incident heart failure. JACC: Heart Failure, 10(7), pp. 498-507. (doi: 10.1016/j.jchf.2022.03.004) (PMID:35772861)

Thorvaldsen, T., Ferrannini, G., Mellbin, L., Benson, L., Cosentino, F., McMurray, J. J.V. , Dahlström, U., Lund, L. H. and Savarese, G. (2022) Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population. Journal of Cardiac Failure, 28(7), pp. 1050-1062. (doi: 10.1016/j.cardfail.2022.04.011) (PMID:35550428)

Waijer, S. W. et al. (2022) Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 65(7), pp. 1085-1097. (doi: 10.1007/s00125-022-05694-6) (PMID:35445820) (PMCID:PMC9174107)

Vaduganathan, M., Claggett, B. L., McMurray, J. J.V. and Solomon, S. D. (2022) Health status trajectories before and after hospitalization for heart failure. Circulation, 145(25), pp. 1872-1874. (doi: 10.1161/CIRCULATIONAHA.122.059282) (PMID:35603665)

Wijkman, M. O. et al. (2022) Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovascular Diabetology, 21, 110. (doi: 10.1186/s12933-022-01545-1) (PMID:35717169) (PMCID:PMC9206286)

Lee, K. K. et al. (2022) Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. British Medical Journal, 377, e068424. (doi: 10.1136/bmj-2021-068424) (PMID:35697365) (PMCID:PMC9189738)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)

Curtain, J. P. et al. (2022) Clinical outcomes related to background diuretic use and new diuretic initiation in patients with HFrEF. JACC: Heart Failure, 10(6), pp. 415-427. (doi: 10.1016/j.jchf.2022.01.020) (PMID:35654526)

Jackson, A. M., Benson, L., Savarese, G., Hage, C., Jhund, P. S. , Petrie, M. C. , Dahlström, U., McMurray, J. J.V. and Lund, L. H. (2022) Apparent treatment-resistant hypertension across the spectrum of heart failure phenotypes in the Swedish HF Registry. JACC: Heart Failure, 10(6), pp. 380-392. (doi: 10.1016/j.jchf.2022.04.006) (PMID:35654522)

McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)

McMurray, J. J.V. and Docherty, K. F. (2022) Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45(S1), S26-S30. (doi: 10.1002/clc.23847) (PMID:35789017) (PMCID:PMC9254667)

Singh, A. K. et al. (2022) Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients. JAMA Internal Medicine, 182(6), pp. 592-602. (doi: 10.1001/jamainternmed.2022.0605) (PMID:35377393) (PMCID:PMC8981070)

Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Cikes, M. et al. (2022) Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure, 10(5), pp. 336-346. (doi: 10.1016/j.jchf.2022.01.018) (PMID:35483796)

De Caterina, R. et al. (2022) Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal: Cardiovascular Pharmacotherapy, 8(3), pp. 227-235. (doi: 10.1093/ehjcvp/pvaa140) (PMID:33367487)

Jhund, P. S. , Docherty, K. F. and McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)

Peikert, A. et al. (2022) Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF. European Journal of Heart Failure, 24(5), pp. 794-803. (doi: 10.1002/ejhf.2450) (PMID:35119183)

Singh, A. K. et al. (2022) Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation, 37(5), pp. 960-972. (doi: 10.1093/ndt/gfab065) (PMID:33744933)

Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)

Wolsk, E. et al. (2022) Risk estimates of imminent cardiovascular death and heart failure hospitalization are improved using serial natriuretic peptide measurements in patients with coronary artery disease and type 2 diabetes. Journal of the American Heart Association, 11(8), e021327. (doi: 10.1161/jaha.121.021327) (PMID:35383463) (PMCID:PMC9238457)

Aune, E., McMurray, J. , Lundgren, P., Sattar, N. , Israelsson, J., Nordberg, P., Herlitz, J. and Rawshani, A. (2022) Clinical characteristics and survival in patients with heart failure experiencing in hospital cardiac arrest. Scientific Reports, 12, 5685. (doi: 10.1038/s41598-022-09510-4) (PMID:35383220) (PMCID:PMC8983650)

Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004) (PMID:36339117) (PMCID:PMC9627879)

Pabón, M. A. et al. (2022) Natriuretic peptide‐based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON‐HF. European Journal of Heart Failure, 24(4), pp. 672-677. (doi: 10.1002/ejhf.2439) (PMID:35080787)

Vart, P. et al. (2022) Efficacy and safety of dapagliflozin in patients with CKD across major geographic regions. Kidney International Reports, 7(4), pp. 699-707. (doi: 10.1016/j.ekir.2022.01.1060) (PMID:35497805) (PMCID:PMC9039473)

Solomon, S. D. et al. (2022) Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal, (doi: 10.1093/eurheartj/ehac144) (PMID:35325102)

Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)

Jackson, A. M. et al. (2022) Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 24(3), pp. 497-509. (doi: 10.1002/ejhf.2403) (PMID:34918855) (PMCID:PMC9542636)

Kondo, T., Jhund, P. S. and McMurray, J. J.V. (2022) Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose? European Journal of Heart Failure, 24(3), pp. 421-430. (doi: 10.1002/ejhf.2447) (PMID:35119172)

Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)

Solomon, S. D. et al. (2022) Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC: Heart Failure, 10(3), pp. 184-197. (doi: 10.1016/j.jchf.2021.11.006) (PMID:35241246)

Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 24(3), pp. 529-538. (doi: 10.1002/ejhf.2350) (PMID:34536265) (PMCID:PMC10654446)

Zahir, D. et al. (2022) Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017. European Journal of Heart Failure, 24(3), pp. 539-547. (doi: 10.1002/ejhf.2418) (PMID:34969178)

Kondo, T. and McMurray, J. J.V. (2022) Re-emergence of heart failure with a normal ejection fraction? European Heart Journal, 43(5), pp. 427-429. (doi: 10.1093/eurheartj/ehab828) (PMID:34878520)

Fiuzat, M. et al. (2022) Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC review topic of the week. Journal of the American College of Cardiology, 79(5), pp. 504-510. (doi: 10.1016/j.jacc.2021.11.033) (PMID:35115106)

Weir, R. A.P., Clements, S., Steedman, T., Dargie, H. J. and McMurray, J. J.V. (2022) Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10 year follow‐up of the Eplerenone Remodeling in Myocardial Infarction without Heart Failure trial. European Journal of Heart Failure, 24(2), pp. 393-395. (doi: 10.1002/ejhf.2402) (PMID:34907636)

Berg, D. D. et al. (2022) Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145(3), pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852) (PMID:34743554)

Chertow, G. M. et al. (2022) Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease. Diabetes, Obesity and Metabolism, 24(5), pp. 827-837. (doi: 10.1111/dom.14641) (PMID:34984791)

Pfeffer, M. A. et al. (2022) Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial. Circulation, 145(1), pp. 87-89. (doi: 10.1161/CIRCULATIONAHA.121.057429) (PMID:34797725)

Felker, G. M. et al. (2022) Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure. JAMA Cardiology, 7(1), pp. 26-34. (doi: 10.1001/jamacardio.2021.4027) (PMID:34643642) (PMCID:PMC8515258)

Heerspink, H. J.L. et al. (2022) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International, 101(1), pp. 174-184. (doi: 10.1016/j.kint.2021.09.005) (PMID:34560136)

Lee, M. M.Y. , Kristensen, S. L., Gerstein, H. C., McMurray, J. J.V. and Sattar, N. (2022) Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 16(1), 102382. (doi: 10.1016/j.dsx.2021.102382) (PMID:35030451)

McMurray, J. J.V. (2022) Can an implanted minipump deliver for diabetes patients? Nature Medicine, 28(1), pp. 27-28. (doi: 10.1038/s41591-021-01628-8) (PMID:34903896)

Rossing, P. et al. (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10(1), pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3) (PMID:34856173)

2021

Singh, A. K. et al. (2021) Daprodustat for the treatment of anemia in patients not undergoing dialysis. New England Journal of Medicine, 385(25), pp. 2313-2324. (doi: 10.1056/NEJMoa2113380) (PMID:34739196)

Singh, A. K. et al. (2021) Daprodustat for the treatment of anemia in patients undergoing dialysis. New England Journal of Medicine, 385(25), pp. 2325-2335. (doi: 10.1056/NEJMoa2113379) (PMID:34739194)

Mooney, L. et al. (2021) Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: insights from PARAGON‐HF. Journal of the American Heart Association, 10(23), e021494. (doi: 10.1161/JAHA.121.021494) (PMID:34796742) (PMCID:PMC9075384)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Codina, P. et al. (2021) Head‐to‐head comparison of contemporary heart failure risk scores. European Journal of Heart Failure, 23(12), pp. 2035-2044. (doi: 10.1002/ejhf.2352) (PMID:34558158)

Desai, A. S. et al. (2021) Mode of death in patients with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation: Heart Failure, 14(12), e008597. (doi: 10.1161/CIRCHEARTFAILURE.121.008597) (PMID:34807713)

Lumbers, R. T. et al. (2021) The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 8(6), pp. 5531-5541. (doi: 10.1002/ehf2.13517) (PMID:34480422) (PMCID:PMC8712846)

Suzuki, K. et al. (2021) Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial. European Journal of Heart Failure, 23(12), pp. 2085-2090. (doi: 10.1002/ejhf.2262) (PMID:34114720)

Vaduganathan, M., Claggett, B. L., Greene, S. J., Aggarwal, R., Bhatt, A. S., McMurray, J. J.V. , Fonarow, G. C. and Solomon, S. D. (2021) Potential implications of expanded US Food and Drug Administration labeling for sacubitril/valsartan in the US. JAMA Cardiology, 6(12), pp. 1415-1423. (doi: 10.1001/jamacardio.2021.3651) (PMID:34524394) (PMCID:PMC8444065)

Waijer, S. W. et al. (2021) The effect of atrasentan on kidney and heart failure outcomes by baseline albuminuria and kidney function: a post hoc analysis of the SONAR randomized trial. Clinical Journal of the American Society of Nephrology, 16(12), pp. 1824-1832. (doi: 10.2215/CJN.07340521) (PMID:34853062)

Mark, P. B. et al. (2021) Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2(11), pp. 1761-1769. (doi: 10.34067/KID.0004272021)

Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)

He, T. et al. (2021) Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 23(11), pp. 1875-1887. (doi: 10.1002/ejhf.2195) (PMID:33881206)

Heerspink, H. J.L. et al. (2021) Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: a prespecified analysis from the SONAR trial. Journal of the American Society of Nephrology, 32(11), pp. 2900-2911. (doi: 10.1681/ASN.2021030391) (PMID:34551995) (PMCID:PMC8806086)

Lee, M. et al. (2021) Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. ESC Congress, 27-30 Aug 2021. (doi: 10.1093/eurheartj/ehab724.1043)

Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

Rush, C. J. et al. (2021) Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiology, 6(10), pp. 1130-1143. (doi: 10.1001/jamacardio.2021.1825) (PMID:34160566) (PMCID:PMC8223134)

Sattar, N. et al. (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology, 9(10), pp. 653-662. (doi: 10.1016/S2213-8587(21)00203-5) (PMID:34425083)

Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)

Jackson, A. M. et al. (2021) Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal, 42(36), pp. 3741-3752. (doi: 10.1093/eurheartj/ehab499) (PMID:34392331) (PMCID:PMC8455346)

Selvaraj, S. et al. (2021) Effects of sacubitril/valsartan on serum lipids in heart failure with preserved ejection fraction. Journal of the American Heart Association, 10(17), e022069. (doi: 10.1161/JAHA.121.022069) (PMID:33998278) (PMCID:PMC8649234)

Bhatt, A. S., Claggett, B. L., Packer, M., Lefkowitz, M. P., Zile, M. R., McMurray, J. J.V. , Solomon, S. D. and Vaduganathan, M. (2021) Treatment effects of sacubitril/valsartan compared with valsartan in patients with recent hospitalization. Journal of Cardiac Failure, 27(9), pp. 1027-1030. (doi: 10.1016/j.cardfail.2021.05.020) (PMID:34133969)

Bhatt, A. S. et al. (2021) Effect of sacubitril/valsartan versus enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial. European Journal of Heart Failure, 23(9), pp. 1518-1524. (doi: 10.1002/ejhf.2259) (PMID:34101308)

Chertow, G. M. et al. (2021) Effects of dapagliflozin in stage 4 chronic kidney disease. Journal of the American Society of Nephrology, 32(9), pp. 2352-2361. (doi: 10.1681/ASN.2021020167) (PMID:34272327) (PMCID:PMC8729835)

Ferreira, J. P. et al. (2021) Dosing of losartan in men vs. women with HFrEF: the HEAAL trial. European Journal of Heart Failure, 23(9), pp. 1477-1484. (doi: 10.1002/ejhf.2255) (PMID:34050594)

Rørth, R. et al. (2021) Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. PLoS ONE, 16(8), e0255364. (doi: 10.1371/journal.pone.0255364) (PMID:34347805) (PMCID:PMC8336831)

Rohde, L. E. et al. (2021) Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. European Journal of Heart Failure, 23(8), pp. 1346-1356. (doi: 10.1002/ejhf.2120) (PMID:33565237)

Shen, L. et al. (2021) Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology, 110(8), pp. 1334-1349. (doi: 10.1007/s00392-021-01888-x) (PMID:34101002)

Shen, L. et al. (2021) Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clinical Research in Cardiology, 110(8), pp. 1234-1248. (doi: 10.1007/s00392-020-01786-8) (PMID:33301080)

Wamil, M., Coleman, R. L., Adler, A. I., McMurray, J. J.V. and Holman, R. R. (2021) Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89. Diabetes Care, 44(8), pp. 1877-1884. (doi: 10.2337/dc21-0429) (PMID:34162666)

Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)

Lee, M. M.Y. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Sattar, N. (2021) Response by Lee et al to letter regarding article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". Circulation, 144(3), e40. (doi: 10.1161/CIRCULATIONAHA.121.055067) (PMID:34279995)

Teerlink, J. R. et al. (2021) Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF. Journal of the American College of Cardiology, 78(2), pp. 97-108. (doi: 10.1016/j.jacc.2021.04.065) (PMID:34015475)

Jhund, P. S. et al. (2021) Heart failure hospitalization in adults receiving maintenance hemodialysis and effect of intravenous iron therapy: A report from PIVOTAL. JACC: Heart Failure, 9(7), pp. 518-527. (doi: 10.1016/j.jchf.2021.04.005) (PMID:34119470)

Lang, N. N. et al. (2021) Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 23(7), pp. 1147-1155. (doi: 10.1002/ejhf.2138) (PMID:33620131)

Simpson, J. et al. (2021) Adherence to prescribed medications in patients with heart failure – insights from liquid chromatography-tandem mass spectrometry-based urine analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 7(4), pp. 296-301. (doi: 10.1093/ehjcvp/pvaa071) (PMID:32597982) (PMCID:PMC8302254)

Solomon, S. D. et al. (2021) Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European Journal of Heart Failure, 23(7), pp. 1217-1225. (doi: 10.1002/ejhf.2249) (PMID:34051124)

Cleland, J. G.F. et al. (2021) The struggle towards a universal definition of heart failure—how to proceed? European Heart Journal, 42(24), pp. 2331-2343. (doi: 10.1093/eurheartj/ehab082) (PMID:33791787)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)

Espersen, C. et al. (2021) Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8(3), pp. 1784-1795. (doi: 10.1002/ehf2.13300) (PMID:33709520) (PMCID:PMC8120385)

Jering, K. S. et al. (2021) Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics. European Journal of Heart Failure, 23(6), pp. 1040-1048. (doi: 10.1002/ejhf.2191) (PMID:33847047)

Packer, M. and McMurray, J. J.V. (2021) Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure, 23(6), pp. 882-894. (doi: 10.1002/ejhf.2149) (PMID:33704874) (PMCID:PMC8360176)

Sørensen, T. B. et al. (2021) The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). European Journal of Heart Failure, 23(6), pp. 1052-1056. (doi: 10.1002/ejhf.2181) (PMID:33826209)

Beggs, S. A.S. , Jhund, P. S. and McMurray, J. J.V. (2021) Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. European Heart Journal, 42(20), e5-e7. (doi: 10.1093/eurheartj/ehy609) (PMID:30357375)

Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)

Berg, D. D. et al. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)

Ferreira, J. P. et al. (2021) Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European Journal of Heart Failure, 23(5), pp. 776-784. (doi: 10.1002/ejhf.2134) (PMID:33609066)

Pellicori, P. et al. (2021) Ultrasound imaging of congestion in heart failure – examinations beyond the heart. European Journal of Heart Failure, 23(5), pp. 703-712. (doi: 10.1002/ejhf.2032) (PMID:33118672)

Shen, L. et al. (2021) Incidence and outcomes of pneumonia in patients with heart failure. Journal of the American College of Cardiology, 77(16), pp. 1961-1973. (doi: 10.1016/j.jacc.2021.03.001) (PMID:33888245)

McMurray, J. J.V. , Solomon, S. D., Docherty, K. F. and Jhund, P. S. (2021) The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 42(13), pp. 1199-1202. (doi: 10.1093/eurheartj/ehz916) (PMID:31898736) (PMCID:PMC8014512)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)

Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)

Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)

Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)

Felker, G. M. et al. (2021) Effects of a novel nitroxyl donor in acute heart failure: the STAND-UP AHF Study. JACC: Heart Failure, 9(2), pp. 146-157. (doi: 10.1016/j.jchf.2020.10.012) (PMID:33248986)

Inzucchi, S. E. et al. (2021) Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44(2), pp. 586-594. (doi: 10.2337/dc20-1675) (PMID:33355302)

Koomen, J. V. et al. (2021) Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: a post hoc analysis of the SONAR trial. Diabetes, Obesity and Metabolism, 23(2), pp. 561-568. (doi: 10.1111/dom.14252) (PMID:33184931) (PMCID:PMC7839558)

Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)

Teerlink, J. R. et al. (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. New England Journal of Medicine, 384, pp. 105-116. (doi: 10.1056/NEJMoa2025797) (PMID:33185990)

McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)

2020

Felker, G. M., Solomon, S. D., McMurray, J. J.V. , Cleland, J. G.F. , Abbasi, S. A., Malik, F. I., Zhang, H., Globe, G. and Teerlink, J. R. (2020) Effects of omecamtiv mecarbil on symptoms and health-related quality of life in patients with chronic heart failure: results from the COSMIC-HF study. Circulation: Heart Failure, 13(12), e007814. (doi: 10.1161/CIRCHEARTFAILURE.120.007814) (PMID:33176437) (PMCID:PMC7742205)

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)

Wamil, M., McMurray, J. J.V. , Scott, C. A.B., Coleman, R. L., Sun, Y., Standl, E., Rydén, L. and Holman, R. R. (2020) Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial. Diabetes Research and Clinical Practice, 170, 108488. (doi: 10.1016/j.diabres.2020.108488) (PMID:33035598)

Yeoh, S. E. et al. (2020) Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. ESC Heart Failure, 7(6), pp. 3355-3364. (doi: 10.1002/ehf2.12972) (PMID:33078584) (PMCID:PMC7754973)

Mackenzie, I. S. et al. (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 396(10264), pp. 1745-1757. (doi: 10.1016/S0140-6736(20)32234-0) (PMID:33181081)

Psotka, M. A. et al. (2020) Conduct of clinical trials in the era of COVID-19: JACC scientific expert panel. Journal of the American College of Cardiology, 76(20), pp. 2368-2378. (doi: 10.1016/j.jacc.2020.09.544) (PMID:33183511)

Dewan, P. et al. (2020) The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 22(11), pp. 2123-2133. (doi: 10.1002/ejhf.1832) (PMID:32353205)

Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)

Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)

Ferreira, J. P., Mogensen, U. M., Jhund, P. S. , Desai, A. S., Zile, M. R., Rossignol, P., Zannad, F., Packer, M., Solomon, S. D. and McMurray, J. J.V. (2020) Serum potassium in the PARADIGM-HF trial. European Journal of Heart Failure, 22(11), pp. 2056-2064. (doi: 10.1002/ejhf.1987) (PMID:32809261) (PMCID:PMC7756204)

McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)

McMurray, J. J.V. (2020) EMPEROR‐Reduced: confirming sodium–glucose co‐transporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 22(11), pp. 1987-1990. (doi: 10.1002/ejhf.2006) (PMID:32946169)

Selvaraj, S. et al. (2020) Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. European Journal of Heart Failure, 22(11), pp. 2093-2101. (doi: 10.1002/ejhf.1984) (PMID:32840930)

Teerlink, J. R. et al. (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 22(11), pp. 2160-2171. (doi: 10.1002/ejhf.2015) (PMID:32985088) (PMCID:PMC7756903)

Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)

Heerspink, H. J.L. et al. (2020) Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), pp. 1436-1446. (doi: 10.1056/NEJMoa2024816) (PMID:32970396)

Wheeler, D. C. et al. (2020) The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 35(10), pp. 1700-1711. (doi: 10.1093/ndt/gfaa234) (PMID:32862232) (PMCID:PMC7538235)

Butt, J. H. et al. (2020) Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. European Journal of Heart Failure, 22(10), pp. 1777-1785. (doi: 10.1002/ejhf.1800) (PMID:32227556)

Dewan, P. , Jhund, P. S. and McMurray, J. J.V. (2020) VICTORIA in context. European Journal of Heart Failure, 22(10), pp. 1747-1751. (doi: 10.1002/ejhf.1833) (PMID:32363731)

Docherty, K. F. , Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)

Malachias, M. V.B. et al. (2020) N-terminal pro-B-type natriuretic peptide by itself predicts death and cardiovascular events in high-risk patients with type 2 diabetes. Journal of the American Heart Association, 9(19), e017462. (doi: 10.1161/JAHA.120.017462) (PMID:32964800) (PMCID:PMC7792415)

Solomon, S. D. et al. (2020) Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan: the DAPA-HF trial. JACC: Heart Failure, 8(10), pp. 811-818. (doi: 10.1016/j.jchf.2020.04.008) (PMID:32653447)

Mc Causland, F. R. et al. (2020) Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation, 142(13), pp. 1236-1245. (doi: 10.1161/CIRCULATIONAHA.120.047643) (PMID:32845715)

Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)

Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)

Sattar, N. et al. (2020) BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 14(5), pp. 1149-1151. (doi: 10.1016/j.dsx.2020.06.060) (PMID:32668401) (PMCID:PMC7326434)

Suzuki, K. et al. (2020) Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 22(9), pp. 1662-1671. (doi: 10.1002/ejhf.1853) (PMID:32407608)

Vaduganathan, M., McMurray, J. J.V. and Solomon, S. D. (2020) Angiotensin receptor–neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON‐HF. European Journal of Heart Failure, 22(9), pp. 1525-1530. (doi: 10.1002/ejhf.1976) (PMID:32741093)

Berglund, E. et al. (2020) Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. European Journal of Preventive Cardiology, 27(12), pp. 1311-1319. (doi: 10.1177/2047487319886959) (PMID:31698965)

Campbell, R. T. et al. (2020) The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 7(4), pp. 1595-1604. (doi: 10.1002/ehf2.12708) (PMID:32383555) (PMCID:PMC7373887)

Rossignol, P. et al. (2020) Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. European Journal of Heart Failure, 22(8), pp. 1402-1411. (doi: 10.1002/ejhf.1724) (PMID:31919958)

Vaduganathan, M., Claggett, B. L., Jhund, P. , Cunningham, J. W., Ferreira, J. P., Zannad, F., Packer, M., Fonarow, G. C., McMurray, J. and Solomon, S. D. (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, 396(10244), pp. 121-128. (doi: 10.1016/S0140-6736(20)30748-0) (PMID:32446323)

Lam, C. S.P., Voors, A. A., Piotr, P., McMurray, J. J.V. and Solomon, S. D. (2020) Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. European Heart Journal, 41(25), pp. 2353-2355. (doi: 10.1093/eurheartj/ehaa158) (PMID:32227233)

Vaduganathan, M. et al. (2020) A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 41(25), pp. 2356-2362. (doi: 10.1093/eurheartj/ehaa184) (PMID:32221596) (PMCID:PMC7327532)

Dewan, P. et al. (2020) Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF. European Journal of Heart Failure, 22(7), pp. 1247-1258. (doi: 10.1002/ejhf.1867) (PMID:32539224)

Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)

Sattar, N. , McInnes, I. B. and McMurray, J. J.V. (2020) Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation, 142(1), pp. 4-6. (doi: 10.1161/CIRCULATIONAHA.120.047659) (PMID:32320270)

Shin, S.-H. et al. (2020) Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure, 22(7), pp. 1133-1143. (doi: 10.1002/ejhf.1790) (PMID:32212368)

Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology 2019: heart failure. Romanian Journal of Cardiology, 30(2), pp. 185-204. (doi: 10.47803/rjc.2020.30.2.185)

Brainin, P. et al. (2020) Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. ESC Heart Failure, 7(3), pp. 1201-1209. (doi: 10.1002/ehf2.12640) (PMID:32077268) (PMCID:PMC7261588)

Cunningham, J. W. et al. (2020) Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC: Heart Failure, 8(5), pp. 372-381. (doi: 10.1016/j.jchf.2020.03.002) (PMID:32241619)

Dewan, P. , Jackson, A., Lam, C. S.P., Pfeffer, M. A., Zannad, F., Pitt, B., Solomon, S. D. and McMurray, J. J.V. (2020) Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. European Journal of Heart Failure, 22(5), pp. 898-901. (doi: 10.1002/ejhf.1776) (PMID:32115864)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Jorsal, A., Pryds, K., McMurray, J. J.V. , Wiggers, H., Sommer, A., Nielsen, J. C. and Nielsen, R. R. (2020) Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical Research in Cardiology, 109(5), pp. 638-645. (doi: 10.1007/s00392-019-01553-4) (PMID:31559483)

Malik, M. E. et al. (2020) Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease. European Journal of Heart Failure, 22(5), pp. 813-820. (doi: 10.1002/ejhf.1819) (PMID:32246806)

Rossello, X., Ferreira, J. P., Pocock, S. J., McMurray, J. J.V. , Solomon, S. D., Lam, C. S.P., Girerd, N., Pitt, B., Rossignol, P. and Zannad, F. (2020) Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. European Journal of Heart Failure, 22(5), pp. 834-844. (doi: 10.1002/ejhf.1740) (PMID:32077220)

Sattar, N. , McMurray, J. J.V. and Cheng, A. (2020) Cardiorenal risk reduction guidance in diabetes: can we reach consensus? Lancet Diabetes and Endocrinology, 8(5), pp. 357-360. (doi: 10.1016/S2213-8587(20)30062-0) (PMID:32171053)

Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)

Selvaraj, S. et al. (2020) Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril/valsartan. Journal of the American College of Cardiology, 75(14), pp. 1644-1656. (doi: 10.1016/j.jacc.2020.02.009) (PMID:32192799)

Macdougall, I. C. et al. (2020) Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial. Journal of the American Society of Nephrology, 31(4), 2019090972. (doi: 10.1681/ASN.2019090972) (PMID:32253271)

Simpson, J. et al. (2020) Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure. JAMA Cardiology, 5(4), pp. 432-441. (doi: 10.1001/jamacardio.2019.5850) (PMID:31995119)

Tardif, J.-C. et al. (2020) Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. American Heart Journal, 222, pp. 157-165. (doi: 10.1016/j.ahj.2020.01.007) (PMID:32087417)

Teerlink, J. R. et al. (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC: Heart Failure, 8(4), pp. 329-340. (doi: 10.1016/j.jchf.2019.12.001) (PMID:32035892)

Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J.V. , Pfeffer, M. A. and Solomon, S. D. (2020) Renin–Angiotensin–Aldosterone System inhibitors in patients with Covid-19. New England Journal of Medicine, 382(17), pp. 1653-1659. (doi: 10.1056/nejmsr2005760) (PMID:32227760)

Cleland, J. G.F. , Lyon, A. R., McDonagh, T. and McMurray, J. J.V. (2020) The year in cardiology: heart failure. European Heart Journal, 41(12), pp. 1232-1248. (doi: 10.1093/eurheartj/ehz949) (PMID:31901936) (PMCID:PMC7084174)

Sharma, A. et al. (2020) Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus. Circulation, 141(10), pp. 843-862. (doi: 10.1161/circulationaha.119.041022) (PMID:31992065)

Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)

Kristensen, S. L. and McMurray, J. J.V. (2020) Diagnosing heart failure with preserved ejection fraction – what's the score? European Journal of Heart Failure, 22(3), pp. 425-427. (doi: 10.1002/ejhf.1764) (PMID:32086989)

Lee, M. M.Y. , Petrie, M. C. , McMurray, J. J.V. and Sattar, N. (2020) How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Arteriosclerosis, Thrombosis, and Vascular Biology, 40(3), pp. 506-522. (doi: 10.1161/atvbaha.119.311904) (PMID:31996025)

Monzo, L. et al. (2020) Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. Journal of Hypertension, 38(3), pp. 420-425. (doi: 10.1097/HJH.0000000000002275) (PMID:31584516)

Shen, L., Jhund, P. and McMurray, J. (2020) Dyslipidaemia, a factor worthy of adjustment: reply. European Journal of Heart Failure, 22(3), pp. 564-565. (doi: 10.1002/ejhf.1718) (PMID:31919977)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

Rorth, R. et al. (2020) Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circulation: Heart Failure, 13(2), e006541. (doi: 10.1161/CIRCHEARTFAILURE.119.006541) (PMID:32065760)

McMurray, J. J.V. et al. (2020) Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF. Circulation, 141(5), pp. 338-351. (doi: 10.1161/CIRCULATIONAHA.119.044491) (PMID:31736337)

Solomon, S. D. et al. (2020) Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation, 141(5), pp. 352-361. (doi: 10.1161/circulationaha.119.044586) (PMID:31736342)

Vaduganathan, M. et al. (2020) Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. Journal of the American College of Cardiology, 75(3), pp. 245-254. (doi: 10.1016/j.jacc.2019.11.003) (PMID:31726194)

Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)

Martinez, F. A. et al. (2020) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation, 141(2), pp. 100-111. (doi: 10.1161/CIRCULATIONAHA.119.044133) (PMID:31736328)

Shah, S. et al. (2020) Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nature Communications, 11, 163. (doi: 10.1038/s41467-019-13690-5) (PMID:31919418) (PMCID:PMC6952380)

Israr, M. Z. et al. (2020) Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT‐CHF. European Journal of Heart Failure, 22(8), pp. 1486-1490. (doi: 10.1002/ejhf.1951) (PMID:32666670)

2019

Kotecha, D. et al. (2019) Impact of renal impairment on beta-blocker efficacy in patients with heart failure. Journal of the American College of Cardiology, 74(23), pp. 2893-2904. (doi: 10.1016/j.jacc.2019.09.059) (PMID:31806133)

Shah, A. M. et al. (2019) Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology, 74(23), pp. 2858-2873. (doi: 10.1016/j.jacc.2019.09.063) (PMID:31806129)

Dewan, P. et al. (2019) Sex-related differences in heart failure with preserved ejection fraction. Circulation: Heart Failure, 12(12), e006539. (doi: 10.1161/CIRCHEARTFAILURE.119.006539) (PMID:31813280)

Ferreira, J. P., Rossello, X., Eschalier, R., McMurray, J. J.V. , Pocock, S., Girerd, N., Rossignol, P., Pitt, B. and Zannad, F. (2019) MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. JACC: Heart Failure, 7(12), pp. 1012-1021. (doi: 10.1016/j.jchf.2019.08.017) (PMID:31779922)

Platz, E., Solomon, S. D. and McMurray, J. J.V. (2019) Lung ultrasound: monitoring congestion in patients with heart failure. European Journal of Heart Failure, 21(12), pp. 1614-1615. (doi: 10.1002/ejhf.1636) (PMID:31702095)

McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)

Ferreira, J. P., Rossignol, P., Dewan, P. , Lamiral, Z., White, W. B., Pitt, B., McMurray, J. J.V. and Zannad, F. (2019) Income level and inequality as complement to geographical differences in cardiovascular trials. American Heart Journal, 218, pp. 66-74. (doi: 10.1016/j.ahj.2019.08.019) (PMID:31707330)

Docherty, K. F. and McMurray, J. J.V. (2019) PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115(13), e136-e139. (doi: 10.1093/cvr/cvz223) (PMID:31497841)

Conrad, N., Judge, A., Canoy, D., Tran, J., Pinho-Gomes, A. C., Millett, E. R.C., Salimi-Khorshidi, G., Cleland, J. G. , McMurray, J. J.V. and Rahimi, K. (2019) Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. JAMA Cardiology, 4(11), pp. 1102-1111. (doi: 10.1001/jamacardio.2019.3593) (PMID:31479100) (PMCID:PMC6724155)

McMurray, J. J.V. et al. (2019) The Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European Journal of Heart Failure, 21(11), pp. 1402-1411. (doi: 10.1002/ejhf.1548) (PMID:31309699)

Solomon, S. D. et al. (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine, 381, pp. 1609-1620. (doi: 10.1056/NEJMoa1908655) (PMID:31475794)

Selvaraj, S. et al. (2019) Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF. Circulation, 140, pp. 1369-1379. (doi: 10.1161/CIRCULATIONAHA.119.039920) (PMID:31510768)

Coiro, S. et al. (2019) Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.1541) (PMID:31476097)

Lee, M. M.Y. , Sattar, N. , McMurray, J. J.V. and Packard, C. J. (2019) Statins in the prevention and treatment of heart failure: a review of the evidence. Current Atherosclerosis Reports, 21(10), 41. (doi: 10.1007/s11883-019-0800-z)

Platz, E. et al. (2019) Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7(10), pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008) (PMID:31582107)

Chandra, A. et al. (2019) Health-related quality of life in heart failure with preserved ejection fraction the PARAGON-HF trial. JACC: Heart Failure, 7(10), pp. 862-874. (doi: 10.1016/j.jchf.2019.05.015) (PMID:31302043)

Yap, J. et al. (2019) Association of diabetes mellitus on cardiac remodeling, quality of life, and clinical outcomes in heart failure with reduced and preserved ejection fraction. Journal of the American Heart Association, 8(17), e013114. (doi: 10.1161/jaha.119.013114) (PMID:31431116)

Beggs, S. A.S. , Rørth, R., Gardner, R. S. and McMurray, J. J.V. (2019) Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart, 105(17), pp. 1325-1334. (doi: 10.1136/heartjnl-2018-314381) (PMID:30962190)

Ferreira, J. P. et al. (2019) World Heart Federation Roadmap for heart failure. Global Heart, 14(3), pp. 197-214. (doi: 10.1016/j.gheart.2019.07.004) (PMID:31451235)

Grodin, J. L. et al. (2019) Prognostic implications of changes in amino-terminal pro–B-type natriuretic peptide in acute decompensated heart failure: insights from ASCEND-HF. Journal of Cardiac Failure, 25(9), pp. 703-711. (doi: 10.1016/j.cardfail.2019.04.002) (PMID:30953792)

Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)

Tromp, J. et al. (2019) Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction. Diabetes Care, 42(9), pp. 1792-1799. (doi: 10.2337/dc18-2515) (PMID:31292141)

Gerstein, H. C., McMurray, J. and Holman, R. R. (2019) The importance of randomised vs non-randomised trials - authors' reply. Lancet, 394(10199), p. 635. (doi: 10.1016/S0140-6736(19)31111-0) (PMID:31448734)

McMurray, J. J.V. and Docherty, K. F. (2019) Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74(7), pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008) (PMID:31416534)

Leong, D. P., McMurray, J. J.V. , Joseph, P. G. and Yusuf, S. (2019) From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure (Part 2/5). Journal of the American College of Cardiology, 74(5), pp. 683-698. (doi: 10.1016/j.jacc.2019.04.068) (PMID:31370961)

Tromp, J. et al. (2019) Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 74(5), pp. 601-612. (doi: 10.1016/j.jacc.2019.05.052) (PMID:31370950)

Felker, G. M., Borentain, M., Cleland, J. G.F. , DeSouza, M. M., Kessler, P. D., O'Connor, C. M., Seiffert, D., Teerlink, J. R., Voors, A. A. and McMurray, J. J.V. (2019) Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 21(8), pp. 1022-1031. (doi: 10.1002/ejhf.1504) (PMID:31168885)

Rørth, R., Dewan, P. , Kristensen, S. L., Jhund, P. S. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2019) Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 108(8), pp. 868-877. (doi: 10.1007/s00392-019-01415-z) (PMID:30689020) (PMCID:PMC6652172)

Shen, L. et al. (2019) Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 21(8), pp. 974-984. (doi: 10.1002/ejhf.1535) (PMID:31271255) (PMCID:PMC7079555)

Chin, K. L., Collier, T., Pocock, S., Pitt, B., McMurray, J. J.V. , van Veldhuisen, D. J., Swedberg, K., Vincent, J., Zannad, F. and Liew, D. (2019) Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. Clinical Research in Cardiology, 108, pp. 806-814. (doi: 10.1007/s00392-018-1410-4) (PMID:30604047)

Platz, E. et al. (2019) Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. European Journal of Heart Failure, 21(7), pp. 844-851. (doi: 10.1002/ejhf.1499)

Robertson, J., Schaufelberger, M., Lindgren, M., Adiels, M., Schiöler, L., Torén, K., McMurray, J. , Sattar, N. , Åberg, M. and Rosengren, A. (2019) Higher body mass index in adolescence predicts cardiomyopathy risk in midlife: long-term follow-up among Swedish men. Circulation, 140, pp. 117-125. (doi: 10.1161/circulationaha.118.039132) (PMID:31132859) (PMCID:PMC6635044)

Stewart, S., Moholdt, T. T., Burrell, L. M., Sliwa, K., Mocumbi, A. O., McMurray, J. J.V. , Keates, A. K. and Hawley, J. A. (2019) Winter peaks in heart failure: an inevitable or preventable consequence of seasonal vulnerability? Cardiac Failure Review, 5(2), pp. 83-85. (doi: 10.15420/cfr.2018.40.2) (PMID:31179017) (PMCID:PMC6546000)

Dewan, P. , Docherty, K. F. and McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)

Ahmad, F. A., Petrie, M. C. , McMurray, J. J.V. and Lang, N. N. (2019) Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 21(6), pp. 699-702. (doi: 10.1002/ejhf.1463) (PMID:30972879) (PMCID:PMC6618029)

Balmforth, C. et al. (2019) Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC: Heart Failure, 7(6), pp. 457-465. (doi: 10.1016/j.jchf.2019.02.015) (PMID:31078482)

Shah, S. J., Voors, A. A., McMurray, J. J.V. , Kitzman, D. W., Viethen, T., Bomfim Wirtz, A., Huang, E., Pap, A. F. and Solomon, S. D. (2019) Effect of neladenoson bialanate on exercise capacity among patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA: Journal of the American Medical Association, 321(21), pp. 2101-2112. (doi: 10.1001/jama.2019.6717) (PMID:31162568) (PMCID:PMC6549300)

Simpson, J., Benson, L., Jhund, P.S. , Dahlström, U., McMurray, J.J.V. and Lund, L.H. (2019) "Real world" eligibility for sacubitril/valsartan in unselected heart failure patients: data from the Swedish Heart Failure Registry. Cardiovascular Drugs and Therapy, 33(3), pp. 315-322. (doi: 10.1007/s10557-019-06873-1) (PMID:30903545) (PMCID:PMC6538576)

Verma, S. and McMurray, J. J.V. (2019) The serendipitous story of SGLT2 inhibitors in heart failure: new insights from DECLARE-TIMI 58. Circulation, 139(22), pp. 2537-2541. (doi: 10.1161/circulationaha.119.040514) (PMID:30882236)

Stienen, S., Ferreira, J. P., Vincent, J., Busselen, M., Li, B., McMurray, J. J.V. , Pitt, B., Girerd, N., Rossignol, P. and Zannad, F. (2019) Estimated long-term survival with eplerenone. Journal of the American College of Cardiology, 73(18), pp. 2357-2359. (doi: 10.1016/j.jacc.2019.02.043) (PMID:31072582)

Rossello, X., Ariti, C., Pocock, S. J., Ferreira, J. P., Girerd, N., McMurray, J. J.V. , Van Veldhuisen, D. J., Pitt, B. and Zannad, F. (2019) Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clinical Research in Cardiology, 108, pp. 477-486. (doi: 10.1007/s00392-018-1378-0) (PMID:30264282)

Conrad, N. et al. (2019) Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: a cohort study of 93,000 UK patients. PLoS Medicine, 16(5), e1002805. (doi: 10.1371/journal.pmed.1002805) (PMID:31112552) (PMCID:PMC6528949)

Dewan, P. et al. (2019) Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 21(5), pp. 577-587. (doi: 10.1002/ejhf.1347) (PMID:30536678) (PMCID:PMC6607486)

Heerspink, H. H.L. et al. (2019) Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, 393(10184), pp. 1937-1947. (doi: 10.1016/S0140-6736(19)30772-X) (PMID:30995972)

McMurray, J. J.V. (2019) Urinalysis: a window to the heart. JACC: Heart Failure, 7(5), pp. 402-403. (doi: 10.1016/j.jchf.2019.04.002)

McMurray, J. J.V. et al. (2019) A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European Journal of Heart Failure, 21(5), pp. 665-675. (doi: 10.1002/ejhf.1432) (PMID:30895697) (PMCID:PMC6607736)

Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)

Docherty, K. F. and McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)

Rossello, X., Ferreira, J. P., McMurray, J. J.V. , Aguilar, D., Pfeffer, M. A., Pitt, B., Dickstein, K., Girerd, N., Rossignol, P. and Zannad, F. (2019) Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 8(3), pp. 231-241. (doi: 10.1177/2048872618803701) (PMID:30259764)

Dewan, P. et al. (2019) Income inequality and outcomes in heart failure: a global between-country analysis. JACC: Heart Failure, 7(4), pp. 336-346. (doi: 10.1016/j.jchf.2018.11.005) (PMID:30738981)

Welsh, P. , Papacosta, O., Ramsay, S., Whincup, P., McMurray, J. , Wannamethee, G. and Sattar, N. (2019) High sensitivity troponin T and incident heart failure in older men: British Regional Heart Study. Journal of Cardiac Failure, 25(4), pp. 230-237. (doi: 10.1016/j.cardfail.2018.08.002) (PMID:30103019) (PMCID:PMC7083232)

Myhre, P. L. et al. (2019) B-type natriuretic peptide during treatment with sacubitril/valsartan: the PARADIGM-HF trial. Journal of the American College of Cardiology, 73(11), pp. 1264-1272. (doi: 10.1016/j.jacc.2019.01.018) (PMID:30846338)

Charytan, D. M. et al. (2019) Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 21(5), pp. 1199-1208. (doi: 10.1111/dom.13642) (PMID:30672083)

Kristensen, S. L. et al. (2019) N-terminal pro-B-type natriuretic peptide levels for risk prediction in patients with heart failure and preserved ejection fraction according to atrial fibrillation status. Circulation: Heart Failure, 12(3), e005766. (doi: 10.1161/circheartfailure.118.005766) (PMID:30871349)

Loader, J. et al. (2019) Prevalence and profile of "seasonal frequent flyers" with chronic heart disease: analysis of 1598 patients and 4588 patient-years follow-up. International Journal of Cardiology, 279, pp. 126-132. (doi: 10.1016/j.ijcard.2018.12.060) (PMID:30638747)

McCausland, F. R. et al. (2019) Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 73(3), pp. 309-315. (doi: 10.1053/j.ajkd.2018.10.006) (PMID:30578152)

Vardeny, O. et al. (2019) Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. European Journal of Heart Failure, pp. 337-341. (doi: 10.1002/ejhf.1402) (PMID:30741494) (PMCID:PMC6607492)

Zile, M. R. et al. (2019) Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. Journal of the American College of Cardiology, 73(7), pp. 795-806. (doi: 10.1016/j.jacc.2018.11.042) (PMID:30784673)

Abraityte, A., Aukrust, P., Kou, L., Anand, I. S., Young, J., McMurray, J. J.V. , van Veldhuisen, D. J., Gullestad, L. and Ueland, T. (2019) T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. Clinical Research in Cardiology, 108(2), pp. 133-141. (doi: 10.1007/s00392-018-1331-2) (PMID:30051179)

Macdougall, I. C. et al. (2019) Intravenous iron in patients undergoing maintenance hemodialysis. New England Journal of Medicine, 380(5), pp. 447-458. (doi: 10.1056/NEJMoa1810742) (PMID:30365356)

Macdougall, I. C. et al. (2019) Correction: Intravenous iron in patients undergoing maintenance hemodialysis. New England Journal of Medicine, 380(5), p. 502. (doi: 10.1056/NEJMx180044) (PMID:30641026)

Gerstein, H. C., McMurray, J. and Holman, R. R. (2019) Real-world studies no substitute for RCTs in establishing efficacy. Lancet, 393(10168), pp. 210-211. (doi: 10.1016/S0140-6736(18)32840-X) (PMID:30663582)

Claggett, B., Pocock, S., Wei, L. J., Pfeffer, M. A., McMurray, J. J.V. and Solomon, S. D. (2019) Response by Claggett et al to letter regarding article, “Comparison of time-to-first event and recurrent-event methods in randomized clinical trials”. Circulation, 139(3), pp. 422-423. (doi: 10.1161/CIRCULATIONAHA.118.038478) (PMID:30640547)

Dewan, P. et al. (2019) Differential impact of heart failure with reduced ejection fraction on men and women. Journal of the American College of Cardiology, 73(1), pp. 29-40. (doi: 10.1016/j.jacc.2018.09.081) (PMID:30621948)

Lee, M. M. Y. , McMurray, J. J.V. , Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. , Jhund, P. S. and Petrie, M. C. (2019) Diabetic cardiomyopathy. Heart, 105(4), pp. 337-345. (doi: 10.1136/heartjnl-2016-310342) (PMID:30337334)

Rørth, R. et al. (2019) The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 21(1), pp. 40-49. (doi: 10.1002/ejhf.1359) (PMID:30537261) (PMCID:PMC6607514)

Bhatt, D. L. et al. (2019) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, 394(10204), pp. 1169-1180. (doi: 10.1016/S0140-6736(19)31887-2) (PMID:31484629)

Ferreira, J. P. et al. (2019) Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial. European Journal of Heart Failure, 21(3), pp. 345-351. (doi: 10.1002/ejhf.1400) (PMID:30768732)

Schultheiss, H.-P. et al. (2019) Dilated cardiomyopathy. Nature Reviews Disease Primers, 5, 32. (doi: 10.1038/s41572-019-0084-1) (PMID:31073128)

Stienen, S., Ferreira, J. P., Girerd, N., Duarte, K., Lamiral, Z., McMurray, J. J.V. , Pitt, B., Dickstein, K., Zannad, F. and Rossignol, P. (2019) Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. Clinical Research in Cardiology, 108(11), pp. 1215-1225. (doi: 10.1007/s00392-019-01453-7) (PMID:30953180)

2018

Tromp, J. et al. (2018) Heart failure with preserved ejection fraction in the young. Circulation, 138(24), pp. 2763-2773. (doi: 10.1161/CIRCULATIONAHA.118.034720) (PMID:30565987)

Beggs, S. A.S. , Gardner, R. S. and McMurray, J. J.V. (2018) Who benefits from a defibrillator—balancing the risk of sudden versus non-sudden death. Current Heart Failure Reports, 15(6), pp. 376-389. (doi: 10.1007/s11897-018-0416-6) (PMID:30413991) (PMCID:PMC6267371)

Bouabdallaoui, N., Claggett, B., Zile, M. R., McMurray, J. J.V. , O'Meara, E., Packer, M., Prescott, M. F., Swedberg, K., Solomon, S. D. and Rouleau, J. L. (2018) Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure, 20(12), pp. 1701-1709. (doi: 10.1002/ejhf.1301) (PMID:30204280)

Campbell, R. T., Petrie, M. C. and McMurray, J. J.V. (2018) Redefining heart failure phenotypes based on ejection fraction. European Journal of Heart Failure, 20(12), pp. 1634-1635. (doi: 10.1002/ejhf.1325) (PMID:30328651)

Campbell, R. T., Petrie, M. C. and McMurray, J. J.V. (2018) Talking to patients with heart failure about end of life. European Journal of Heart Failure, 20(12), pp. 1763-1765. (doi: 10.1002/ejhf.1321) (PMID:30295978) (PMCID:PMC6607510)

Idzerda, N. M.A., Persson, F., Pena, M. J., Brenner, B. M., Brunel, P., Chaturvedi, N., McMurray, J. J. , Parving, H.-H., de Zeeuw, D. and Heerspink, H. J.L. (2018) N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes, Obesity and Metabolism, 20(12), pp. 2899-2904. (doi: 10.1111/dom.13465) (PMID:29987919) (PMCID:PMC6282705)

Ramires, F. J.A. et al. (2018) Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al. ESC Heart Failure, 5(6), pp. 1069-1071. (doi: 10.1002/ehf2.12355) (PMID:30298996) (PMCID:PMC6300803)

Srivastava, P. K., Claggett, B. L., Solomon, S. D., McMurray, J. J.V. , Packer, M., Zile, M. R., Desai, A. S., Rouleau, J. L., Swedberg, K. and Fonarow, G. C. (2018) Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial. JAMA Cardiology, 3(12), pp. 1226-1231. (doi: 10.1001/jamacardio.2018.3957) (PMID:30484837) (PMCID:PMC6583093)

Fudim, M. et al. (2018) Relation of volume overload to clinical outcomes in acute heart failure (from ASCEND-HF). American Journal of Cardiology, 122(9), pp. 1506-1512. (doi: 10.1016/j.amjcard.2018.07.023) (PMID:30172362) (PMCID:PMC6924269)

Kristensen, S. L., Rørth, R., Jhund, P. S. , Shen, L., Lee, M. M.Y. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2018) Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial. European Journal of Heart Failure, 20(11), pp. 1549-1556. (doi: 10.1002/ejhf.1201) (PMID:29727039)

Voors, A. A. et al. (2018) Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 20(11), pp. 1601-16010. (doi: 10.1002/ejhf.1295) (PMID:30225882)

Hernandez, A. F. et al. (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, 392(10157), pp. 1519-1529. (doi: 10.1016/S0140-6736(18)32261-X) (PMID:30291013)

Haynes, R. et al. (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial. Circulation, 138(15), pp. 1505-1514. (doi: 10.1161/CIRCULATIONAHA.118.034818) (PMID:30002098)

Rush, C. J., Campbell, R. T., Jhund, P. S. , Petrie, M. C. and McMurray, J. J.V. (2018) Association is not causation: treatment effects cannot be estimated from observational data in heart failure. European Heart Journal, 39(37), pp. 3417-3438. (doi: 10.1093/eurheartj/ehy407) (PMID:30085087) (PMCID:PMC6166137)

Cosmi, F., Staszewsky, L., McMurray, J. J.V. and Latini, R. (2018) Risk stratification according to insulin type: reply. European Journal of Heart Failure, 20(10), p. 1498. (doi: 10.1002/ejhf.1218) (PMID:29851246)

Januzzi, J. L. et al. (2018) IGFBP7 (insulin-like growth factor–binding protein-7) and neprilysin inhibition in patients with heart failure. Circulation: Heart Failure, 11(10), e005133. (doi: 10.1161/circheartfailure.118.005133) (PMID:30354399)

Campbell, R. T. et al. (2018) Which patients with heart failure should receive specialist palliative care? European Journal of Heart Failure, 20(9), pp. 1338-1347. (doi: 10.1002/ejhf.1240) (PMID:29952090) (PMCID:PMC6607479)

Green, J. B. et al. (2018) Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-rationale, design, and baseline characteristics. American Heart Journal, 203, pp. 30-38. (doi: 10.1016/j.ahj.2018.03.030) (PMID:30015066)

Ueland, T., Gullestad, L., Kou, L., Aukrust, P., Anand, I. S., Broughton, M. N., McMurray, J. J. , van Veldhuisen, D. J., Warren, D. J. and Bolstad, N. (2018) Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study. ESC Heart Failure, 5(6), pp. 1052-1059. (doi: 10.1002/ehf2.12312) (PMID:30145817) (PMCID:PMC6300802)

Claggett, B., Pocock, S., Wei, L.J., Pfeffer, M. A., McMurray, J. J.V. and Solomon, S. D. (2018) Comparison of time-to-first event and recurrent event methods in randomized clinical trials. Circulation, 138(6), pp. 570-577. (doi: 10.1161/CIRCULATIONAHA.117.033065) (PMID:29588314)

Docherty, K. F. , Jhund, P. S. and McMurray, J. J.V. (2018) Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379(5), pp. 491-492. (doi: 10.1056/NEJMc1806519) (PMID:30070094)

Ferreira, J. P., Duarte, K., Pitt, B., Dickstein, K., McMurray, J. J.V. , Zannad, F. and Rossignol, P. (2018) Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure: findings from the EPHESUS and OPTIMAAL trials. Journal of Hypertension, 36(8), pp. 1736-1742. (doi: 10.1097/HJH.0000000000001742) (PMID:29683884)

Grodin, J. L. et al. (2018) Circulating cardiac troponin I levels measured by a novel highly sensitive assay in acute decompensated heart failure: insights from the ASCEND-HF trial. Journal of Cardiac Failure, 24(8), pp. 512-519. (doi: 10.1016/j.cardfail.2018.06.008) (PMID:30012361)

Heerspink, H. J.L. et al. (2018) Baseline characteristics and enrichment results from the SONAR trial. Diabetes, Obesity and Metabolism, 20(8), pp. 1829-1835. (doi: 10.1111/dom.13315) (PMID:29604160)

Lund, L. H. et al. (2018) Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 20(8), pp. 1230-1239. (doi: 10.1002/ejhf.1149) (PMID:29431256)

Abdul-Rahim, A. H. , Shen, L., Rush, C. J., Jhund, P. S. , Lees, K. R. and McMurray, J. J.V. (2018) Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. European Journal of Heart Failure, 20(7), pp. 1139-1145. (doi: 10.1002/ejhf.1160) (PMID:29493058)

Ferreira, J. P., Duarte, K., McMurray, J. J.V. , Pitt, B., van Veldhuisen, D. J., Vincent, J., Ahmad, T., Tromp, J., Rossignol, P. and Zannad, F. (2018) Data-driven approach to identify subgroups of heart failure with reduced ejection fraction patients with different prognoses and aldosterone antagonist response patterns. Circulation: Heart Failure, 11(7), e004926. (doi: 10.1161/CIRCHEARTFAILURE.118.004926) (PMID:29997240)

Packer, M., Claggett, B., Lefkowitz, M. P., McMurray, J. J.V. , Rouleau, J. L., Solomon, S. D. and Zile, M. R. (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes and Endocrinology, 6(7), pp. 547-554. (doi: 10.1016/S2213-8587(18)30100-1) (PMID:29661699)

Solomon, S. D. et al. (2018) Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure, 11(7), e004962. (doi: 10.1161/CIRCHEARTFAILURE.118.004962) (PMID:29980595)

Vaduganathan, M., Claggett, B., Packer, M., McMurray, J. J.V. , Rouleau, J. L., Zile, M. R., Swedberg, K. and Solomon, S. D. (2018) Natriuretic peptides as biomarkers of treatment response in clinical trials of heart failure. JACC: Heart Failure, 6(7), pp. 564-569. (doi: 10.1016/j.jchf.2018.02.007) (PMID:29501807)

McMurray, J. J.V. (2018) Only trials tell the truth about treatment effects. Journal of the American College of Cardiology, 71(23), pp. 2640-2642. (doi: 10.1016/j.jacc.2018.04.019) (PMID:29880123)

Rørth, R., Jhund, P. S. , Mogensen, U. M., Kristensen, S. L., Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2018) Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction. Diabetes Care, 41(6), pp. 1285-1291. (doi: 10.2337/dc17-2583) (PMID:29626073)

Chanfra, A. et al. (2018) Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology, 3(6), pp. 498-505. (doi: 10.1001/jamacardio.2018.0398) (PMID:29617523) (PMCID:PMC6128510)

Damman, K. et al. (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC: Heart Failure, 6(6), pp. 489-498. (doi: 10.1016/j.jchf.2018.02.004) (PMID:29655829)

Heerspink, H. J.L. et al. (2018) Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes, Obesity and Metabolism, 20(6), pp. 1369-1376. (doi: 10.1111/dom.13245) (PMID:29405626)

McMurray, J. J.V. et al. (2018) Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart, 104(12), pp. 1006-1013. (doi: 10.1136/heartjnl-2016-310661) (PMID:29269379) (PMCID:PMC5992367)

Simpson, J. and McMurray, J. J.V. (2018) Prognostic modeling in heart failure: time for a reboot. JACC: Heart Failure, 6(6), pp. 463-464. (doi: 10.1016/j.jchf.2018.03.020) (PMID:29852930)

Frikha, Z., Ferreira, J. P., Bozec, E., McMurray, J. J.V. , Pitt, B., Dickstein, K., Rossignol, P., Zannad, F. and Girerd, N. (2018) Relation of high serum bilirubin to short-term mortality following a myocardial infarction complicated by left ventricular systolic dysfunction (from the High-Risk Myocardial Infarction Database Initiative). American Journal of Cardiology, 121(9), pp. 1015-1020. (doi: 10.1016/j.amjcard.2018.01.012) (PMID:29631805)

Cosmi, F. et al. (2018) Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure, 20(5), pp. 888-895. (doi: 10.1002/ejhf.1146) (PMID:29488676)

Lupón, J. et al. (2018) Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. European Journal of Heart Failure, 20(5), pp. 938-940. (doi: 10.1002/ejhf.949) (PMID:28949101)

O'Meara, E., Prescott, M. F., Claggett, B., Rouleau, J. L., Chiang, L.-M., Solomon, S. D., Packer, M., McMurray, J. J.V. and Zile, M. R. (2018) Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF Trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure). Circulation: Heart Failure, 11(5), e004446. (doi: 10.1161/CIRCHEARTFAILURE.117.004446) (PMID:29748349)

Seferović, P. M. et al. (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 20(5), pp. 853-872. (doi: 10.1002/ejhf.1170) (PMID:29520964)

Theodorakis, M. J. et al. (2018) Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal, 199, pp. 170-175. (doi: 10.1016/j.ahj.2017.09.001) (PMID:29754657)

McMurray, J. J.V. (2018) Renin–angiotensin system inhibition—it's been a long but fruitful journey. European Journal of Heart Failure, 20(4), pp. 687-688. (doi: 10.1002/ejhf.1155) (PMID:29405513)

Mogensen, U. M. et al. (2018) Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). European Journal of Heart Failure, 20(4), pp. 760-768. (doi: 10.1002/ejhf.1139) (PMID:29431251)

Vardeny, O. et al. (2018) Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure). Circulation: Heart Failure, 11(4), e004745. (doi: 10.1161/CIRCHEARTFAILURE.117.004745) (PMID:29643067)

Tromp, J. et al. (2018) Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Medicine, 15(3), e1002541. (doi: 10.1371/journal.pmed.1002541) (PMID:29584721) (PMCID:PMC5870945)

Bethel, M. A. and McMurray, J. J.V. (2018) Class effect for sodium glucose-cotransporter-2 inhibitors in cardiovascular outcomes: implications for the cardiovascular disease specialist. Circulation, 137(12), pp. 1218-1220. (doi: 10.1161/CIRCULATIONAHA.117.030117) (PMID:29555706)

Hicks, K. A. et al. (2018) 2017 cardiovascular and stroke endpoint definitions for clinical trials. Journal of the American College of Cardiology, 71(9), pp. 1021-1034. (doi: 10.1016/j.jacc.2017.12.048) (PMID:29495982)

Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J.V. and Boulton, D. W. (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes, Obesity and Metabolism, 20(3), pp. 479-487. (doi: 10.1111/dom.13126) (PMID:29024278)

Jorsal, A., Wiggers, H. and McMurray, J. J.V. (2018) Heart failure: epidemiology, pathophysiology, and management of heart failure in diabetes mellitus. Endocrinology and Metabolism Clinics of North America, 47(1), pp. 117-135. (doi: 10.1016/j.ecl.2017.10.007) (PMID:29407047)

Mogensen, U. M. et al. (2018) Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. European Journal of Heart Failure, 20(3), pp. 514-522. (doi: 10.1002/ejhf.1056) (PMID:29193563)

Seferovic, J. P., Pfeffer, M. A., Claggett, B., Desai, A. S., de Zeeuw, D., Haffner, S. M., McMurray, J. J.V. , Parving, H.-H., Solomon, S. D. and Chaturvedi, N. (2018) Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia, 61(3), pp. 581-588. (doi: 10.1007/s00125-017-4485-y) (PMID:29098323)

Wolsk, E., Claggett, B., Køber, L., Pocock, S., Yusuf, S., Swedberg, K., McMurray, J. J.V. , Granger, C. B., Pfeffer, M. A. and Solomon, S. D. (2018) Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. European Journal of Heart Failure, 20(3), pp. 504-510. (doi: 10.1002/ejhf.1073) (PMID:29193462)

Hicks, K. A. et al. (2018) 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation, 137(9), pp. 961-972. (doi: 10.1161/CIRCULATIONAHA.117.033502) (PMID:29483172)

Ferreira, J. P. et al. (2018) Stroke risk in patients with reduced ejection fraction after myocardial infarction without atrial fibrillation. Journal of the American College of Cardiology, 71(7), pp. 727-735. (doi: 10.1016/j.jacc.2017.12.011) (PMID:29447733)

Conrad, N. et al. (2018) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet, 391(10120), pp. 10-16. (doi: 10.1016/S0140-6736(17)32520-5) (PMID:29174292) (PMCID:PMC5814791)

Cotter, G. et al. (2018) Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? European Journal of Heart Failure, 20(2), pp. 317-322. (doi: 10.1002/ejhf.889) (PMID:28871621)

Ferreira, J. P., Duarte, K., Pfeffer, M. A., McMurray, J. J.V. , Pitt, B., Dickstein, K., Zannad, F. and Rossignol, P. (2018) Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure, 20(2), pp. 323-331. (doi: 10.1002/ejhf.1131) (PMID:29314455)

Platz, E., Jhund, P. S. , Claggett, B. L., Pfeffer, M. A., Swedberg, K., Granger, C. B., Yusuf, S., Solomon, S. D. and McMurray, J. J. (2018) Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. European Journal of Heart Failure, 20(2), pp. 295-303. (doi: 10.1002/ejhf.901) (PMID:28872259)

Rørth, R. et al. (2018) Employment status at time of first hospitalization for heart failure is associated with death and rehospitalization for heart failure. European Journal of Heart Failure, 20(2), pp. 240-247. (doi: 10.1002/ejhf.1046) (PMID:29148231)

Schwartz, G. G. et al. (2018) Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome. JAMA Cardiology, 3(2), pp. 164-168. (doi: 10.1001/jamacardio.2017.3833) (PMID:29071331) (PMCID:PMC5838593)

van der Meer, P. et al. (2018) Hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF study (Reduction of Events by Darbepoetin Alfa in Heart Failure): clinical and prognostic associations. Circulation: Heart Failure, 11(2), e004431. (doi: 10.1161/CIRCHEARTFAILURE.117.004431) (PMID:29367268)

Welsh, P. et al. (2018) Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. European Journal of Heart Failure, 20(2), pp. 268-277. (doi: 10.1002/ejhf.988) (PMID:28960777) (PMCID:PMC6607475)

Cleland, J. G.F. et al. (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 39(1), pp. 26-35. (doi: 10.1093/eurheartj/ehx564) (PMID:29040525)

Masip, J. et al. (2018) Indications and practical approach to non-invasive ventilation in acute heart failure. European Heart Journal, 39(1), pp. 17-25. (doi: 10.1093/eurheartj/ehx580) (PMID:29186485)

Beggs, S. A.S. , Jhund, P. S. , Jackson, C. E., McMurray, J. J.V. and Gardner, R. S. (2018) Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart, 104(2), pp. 144-150. (doi: 10.1136/heartjnl-2016-310850) (PMID:28986406)

Kristensen, S. L. et al. (2018) Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial. European Journal of Heart Failure, 20(1), pp. 136-147. (doi: 10.1002/ejhf.896) (PMID:28948656)

McMurray, J. J.V. , Ponikowski, P., Bolli, G. B., Lukashevich, V., Kozlovski, P., Kothny, W., Lewsey, J. D. and Krum, H. (2018) Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC: Heart Failure, 6(1), pp. 8-17. (doi: 10.1016/j.jchf.2017.08.004) (PMID:29032139)

Rørth, R. et al. (2018) Evidence based therapy and its association with workforce detachment following first hospitalization for heart failure. JACC: Heart Failure, 6(1), pp. 41-48. (doi: 10.1016/j.jchf.2017.09.019) (PMID:29226811)

Kraus, W. E., Yates, T., Tuomilehto, J., Sun, J.-L., Thomas, L., McMurray, J. J.V. , Bethel, M. A. and Holman, R. R. (2018) Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. BMJ Open Diabetes Research and Care, 6, e000523. (doi: 10.1136/bmjdrc-2018-000523) (PMID:30073088) (PMCID:PMC6067333)

Macdougall, I. C. et al. (2018) Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL): study design and baseline data. American Journal of Nephrology, 48(4), pp. 260-268. (doi: 10.1159/000493551) (PMID:30304714)

McAllister, D. A. et al. (2018) Incidence of hospitalisation for heart failure and case-fatality among 3.25 million people with and without diabetes. Circulation, 138(24), pp. 2774-2785. (doi: 10.1161/CIRCULATIONAHA.118.034986) (PMID:29950404) (PMCID:PMC6287897)

Rørth, R. et al. (2018) Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure: a nationwide cohort study. Clinical Epidemiology, 10, pp. 917-930. (doi: 10.2147/CLEP.S164795) (PMID:30123004) (PMCID:PMC6080879)

Seferovic, J. P. et al. (2018) Retinopathy, neuropathy, and subsequent cardiovascular events in patients with type 2 diabetes and acute coronary syndrome in the ELIXA: the importance of disease duration. Journal of Diabetes Research, 2018, 1631263. (doi: 10.1155/2018/1631263) (PMID:30648112) (PMCID:PMC6311850)

Verma, S. and McMurray, J. J.V. (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(10), pp. 2108-2117. (doi: 10.1007/s00125-018-4670-7) (PMID:30132036)

2017

Kristensen, S. L., Jhund, P. S. , Lee, M. M.Y. , Køber, L., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K. and McMurray, J. J.V. (2017) Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovascular Drugs and Therapy, 31(5-6), pp. 545-549. (doi: 10.1007/s10557-017-6754-x) (PMID:28948430)

Senni, M., McMurray, J. J.V. , Wachter, R., McIntyre, H. F., Anand, I. S., Duino, V., Sarkar, A., Shi, V. and Charney, A. (2017) Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. European Journal of Heart Failure, 20(3), pp. 491-500. (doi: 10.1002/ejhf.1054) (PMID:29164797)

Shen, L., Jhund, P. S. and McMurray, J. J.V. (2017) Declining risk of sudden death in heart failure. New England Journal of Medicine, 377(18), pp. 1794-1795. (doi: 10.1056/NEJMc1711901) (PMID:29091558)

Holman, R. R. et al. (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology, 5(11), pp. 877-886. (doi: 10.1016/S2213-8587(17)30309-1) (PMID:28917545)

McDonald, M. A. et al. (2017) Mind the gap: current challenges and future state of heart failure care. Canadian Journal of Cardiology, 33(11), pp. 1434-1449. (doi: 10.1016/j.cjca.2017.08.023) (PMID:29111107)

Mogensen, U. M. et al. (2017) Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction. Journal of the American College of Cardiology, 70(20), pp. 2490-2500. (doi: 10.1016/j.jacc.2017.09.027) (PMID:29145948)

Shen, L. et al. (2017) Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circulation: Heart Failure, 10(11), e004361. (doi: 10.1161/CIRCHEARTFAILURE.117.004361) (PMID:29141857)

Stewart, S., Keates, A. K., Redfern, A. and McMurray, J. J.V. (2017) Seasonal variations in cardiovascular disease. Nature Reviews Cardiology, 14(11), pp. 654-664. (doi: 10.1038/nrcardio.2017.76) (PMID:28518176)

Wong, C. M. et al. (2017) Heart failure in young adults is associated with high mortality: a contemporary population-level analysis. Canadian Journal of Cardiology, 33(11), pp. 1472-1477. (doi: 10.1016/j.cjca.2017.05.009) (PMID:28941947)

Wolsk, E. et al. (2017) Increases in natriuretic peptides precede heart failure hospitalization in patients with a recent coronary event and type 2 diabetes mellitus. Circulation, 136(16), pp. 1560-1562. (doi: 10.1161/CIRCULATIONAHA.117.029503) (PMID:29038210)

Charytan, D. M. et al. (2017) ESRD after heart failure, myocardial infarction, or stroke in type 2 diabetic patients with CKD. American Journal of Kidney Diseases, 70(4), pp. 522-531. (doi: 10.1053/j.ajkd.2017.04.018) (PMID:28599901)

Kristensen, S. L. et al. (2017) Prognostic value of N-terminal pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation. Circulation: Heart Failure, 10(10), e004409. (doi: 10.1161/CIRCHEARTFAILURE.117.004409) (PMID:29018174)

Griffin, E. A. et al. (2017) Cost-effectiveness analysis of natriuretic peptide testing and specialist management in patients with suspected acute heart failure. Value in Health, 20(8), pp. 1025-1033. (doi: 10.1016/j.jval.2017.05.007) (PMID:28964433)

Olivier, A. et al. (2017) Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: insight from the EMPHASIS-HF trial. European Journal of Heart Failure, 19(9), pp. 1186-1197. (doi: 10.1002/ejhf.792) (PMID:28303624)

Platz, E., Merz, A. A., Jhund, P. S. , Vazir, A., Campbell, R. and McMurray, J. J. (2017) Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. European Journal of Heart Failure, 19(9), pp. 1154-1163. (doi: 10.1002/ejhf.839) (PMID:28557302)

Verma, S., McMurray, J. J.V. and Cherney, D. Z.I. (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiology, 2(9), pp. 939-940. (doi: 10.1001/jamacardio.2017.1891) (PMID:28636701)

Baigent, C. et al. (2017) Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 92(2), pp. 297-305. (doi: 10.1016/j.kint.2017.04.019) (PMID:28709600)

Lewis, E. F. et al. (2017) Health-related quality of life outcomes in PARADIGM-HF. Circulation: Heart Failure, 10(8), e003430. (doi: 10.1161/CIRCHEARTFAILURE.116.003430) (PMID:28784687)

Shen, L., Jhund, P. S. , Mogensen, U. M., Køber, L., Claggett, B., Rogers, J. K. and McMurray, J. J.V. (2017) A re-examination of the BEST Trial using composite outcomes, including emergency department visits. JACC: Heart Failure, 5(8), pp. 591-599. (doi: 10.1016/j.jchf.2017.04.005) (PMID:28774394)

Shen, L. et al. (2017) Declining risk of sudden death in heart failure. New England Journal of Medicine, 377(1), pp. 41-51. (doi: 10.1056/NEJMoa1609758) (PMID:28679089)

Price, S. et al. (2017) Expert consensus document: echocardiography and lung ultrasonography for the assessment and management of acute heart failure. Nature Reviews Cardiology, 14(7), pp. 427-440. (doi: 10.1038/nrcardio.2017.56) (PMID:28447662)

Solomon, S. D. et al. (2017) Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction. JACC: Heart Failure, 5(7), pp. 471-482. (doi: 10.1016/j.jchf.2017.04.013) (PMID:28662936)

MacDonald, T. M. et al. (2017) Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). European Heart Journal, 38(23), pp. 1843-1850. (doi: 10.1093/eurheartj/ehw387) (PMID:27705888) (PMCID:PMC5837371)

Cleland, J. G.F. et al. (2017) Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). European Journal of Heart Failure, 19(6), pp. 739-747. (doi: 10.1002/ejhf.786) (PMID:28296139)

Cowie, M. R. et al. (2017) New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. European Journal of Heart Failure, 19(6), pp. 718-727. (doi: 10.1002/ejhf.809) (PMID:28345190)

Currie, G. , Bethel, M. A., Holzhauer, B., Haffner, S. M., Holman, R. R. and McMurray, J. J.V. (2017) Effect of valsartan on kidney outcomes in people with impaired glucose tolerance. Diabetes, Obesity and Metabolism, 19(6), pp. 791-799. (doi: 10.1111/dom.12877) (PMID:28093841)

Guimarães, P. O. et al. (2017) Effect of Apixaban on all-cause death in patients with atrial fibrillation: a meta-analysis based on imputed placebo effect. Cardiovascular Drugs and Therapy, 31(3), pp. 295-301. (doi: 10.1007/s10557-017-6728-z) (PMID:28516318)

Mogensen, U. M. et al. (2017) The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 188, pp. 35-41. (doi: 10.1016/j.ahj.2017.02.034) (PMID:28577679)

Rossignol, P. et al. (2017) Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. European Journal of Heart Failure, 19(6), pp. 792-799. (doi: 10.1002/ejhf.688) (PMID:27868385)

Wolsk, E. et al. (2017) Role of b-type natriuretic peptide and n-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus. Journal of the American Heart Association, 6(6), e004743. (doi: 10.1161/JAHA.116.004743) (PMID:28554908)

Packer, M. et al. (2017) Effect of ularitide on cardiovascular mortality in acute heart failure. New England Journal of Medicine, 376(20), pp. 1956-1964. (doi: 10.1056/NEJMoa1601895) (PMID:28402745)

Packer, M. and McMurray, J. J.V. (2017) Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet, 389(10081), pp. 1831-1840. (doi: 10.1016/S0140-6736(16)30969-2) (PMID:27919443)

Bethel, M. A. et al. (2017) Updated risk factors should be used to predict development of diabetes. Journal of Diabetes and its Complications, 31(5), pp. 859-863. (doi: 10.1016/j.jdiacomp.2017.02.012) (PMID:28319004)

Cowper, P. A. et al. (2017) Economic analysis of apixaban therapy for patients with atrial fibrillation from a US perspective: results from the ARISTOTLE randomized clinical trial. JAMA Cardiology, 2(5), pp. 525-534. (doi: 10.1001/jamacardio.2017.0065) (PMID:28355434)

Ho, C. Y. et al. (2017) Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: the design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial. American Heart Journal, 187, pp. 145-155. (doi: 10.1016/j.ahj.2017.02.008) (PMID:28454798) (PMCID:PMC5586211)

Packer, M. et al. (2017) Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. European Journal of Heart Failure, 19(5), pp. 673-681. (doi: 10.1002/ejhf.698) (PMID:27862700)

Packer, M. et al. (2017) Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure : primary results of the ENABLE Trials. JACC: Heart Failure, 5(5), pp. 317-326. (doi: 10.1016/j.jchf.2017.02.021) (PMID:28449795)

Seferovic, J. P. et al. (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes and Endocrinology, 5(5), pp. 333-340. (doi: 10.1016/S2213-8587(17)30087-6) (PMID:28330649) (PMCID:PMC5534167)

Cannon, J. A., Moffitt, P., Perez-Moreno, A. C., Walters, M. R. , Broomfield, N. M., McMurray, J. J.V. and Quinn, T. J. (2017) Cognitive impairment and heart failure: systematic review and meta-analysis. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2017.04.007) (PMID:28433667)

Böhm, M. et al. (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 38(15), pp. 1132-1143. (doi: 10.1093/eurheartj/ehw570) (PMID:28158398)

Nymo, S. H. et al. (2017) Limited added value of circulating inflammatory biomarkers in chronic heart failure. JACC: Heart Failure, 5(4), pp. 256-264. (doi: 10.1016/j.jchf.2017.01.008) (PMID:28359413)

Abdul-Rahim, A. H. et al. (2017) Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. European Heart Journal, 38(10), pp. 742-750. (doi: 10.1093/eurheartj/ehw509) (PMID:28426886) (PMCID:PMC5460584)

Docherty, K. F. , Campbell, R. T., Jhund, P. , Petrie, M. C. and McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)

Emdin, C. A. et al. (2017) Referral for specialist follow-up and its association with post-discharge mortality among patients with systolic heart failure (from the National Heart Failure Audit for England and Wales). American Journal of Cardiology, 119(3), pp. 440-444. (doi: 10.1016/j.amjcard.2016.10.021) (PMID:27884420) (PMCID:PMC5282396)

Beldhuis, I. E., Streng, K. W., Ter Maaten, J. M., Voors, A. A., van der Meer, P., Rossignol, P., McMurray, J. J.V. and Damman, K. (2017) Renin–angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction. Circulation: Heart Failure, 10(2), e003588. (doi: 10.1161/CIRCHEARTFAILURE.116.003588) (PMID:28209765)

Ferreira, J. P. et al. (2017) Serum chloride and sodium interplay in patients with acute myocardial infarction and heart failure with reduced ejection fraction. Circulation: Heart Failure, 10(2), e003500. (doi: 10.1161/CIRCHEARTFAILURE.116.003500) (PMID:28159825)

Kitai, T. et al. (2017) Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. European Journal of Heart Failure, 19(2), pp. 241-249. (doi: 10.1002/ejhf.629) (PMID:27634557)

Mueller, C. et al. (2017) European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care. European Heart Journal: Acute Cardiovascular Care, 6(1), pp. 81-86. (doi: 10.1177/2048872615593279) (PMID:26124458)

Paton, D. M., Shamy, M., Fedyk, M., Pfeffer, M. A. and McMurray, J. J.V. (2017) Clinical trials involving hypertension [Correspondence]. New England Journal of Medicine, 376(3), pp. 289-290. (doi: 10.1056/NEJMc1615364) (PMID:28099831)

Agewall, S. et al. (2017) 2016 ESC guidelines for the diagnosis and treatment of atrial fibrillation developed in collaboration with the EACTS [Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS]. Revista Española de Cardiología, 70(1), 50.e1-50.e84. (doi: 10.1016/j.recesp.2016.11.014)

Hawkins, N. M., Khosla, A., Virani, S. A., McMurray, J. J.V. and FitzGerald, J. M. (2017) B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulmonary Medicine, 17, 11. (doi: 10.1186/s12890-016-0345-7) (PMID:28073350) (PMCID:PMC5223538)

Cannon, J. A. et al. (2017) Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 19(1), pp. 129-137. (doi: 10.1002/ejhf.687) (PMID:27868321) (PMCID:PMC5248626)

Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J.V. , Deschaseaux, C. and Cope, S. (2017) Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circulation: Heart Failure, 10, e003529. (doi: 10.1161/CIRCHEARTFAILURE.116.003529) (PMID:28087688)

Desai, A. S. et al. (2017) Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of Sacubitril/Valsartan compared with Enalapril: A secondary analysis of the PARADIGM-HF Trial. JAMA Cardiology, 2(1), pp. 79-85. (doi: 10.1001/jamacardio.2016.4733) (PMID:27842179)

Gandhi, P. U. et al. (2017) Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure, 23(1), pp. 20-28. (doi: 10.1016/j.cardfail.2016.06.006) (PMID:27317843)

Kristensen, S. L. et al. (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve). Circulation, 135(8), pp. 724-735. (doi: 10.1161/CIRCULATIONAHA.116.024593) (PMID:28052977)

Arain, F., Gullestad, L., Nymo, S., Kjekshus, J., Cleland, J. G.F. , Michelsen, A., McMurray, J. J.V. , Wikstrand, J., Aukrust, P. and Ueland, T. (2017) Low YKL-40 in Chronic Heart Failure may predict beneficial effects of statins: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Biomarkers, 22, pp. 261-267. (doi: 10.1080/1354750X.2016.1204003) (PMID:27325138)

Harumi Higuchi dos Santos, M., Sharma, A., Sun, J.‐L., Pieper, K., McMurray, J. J.V. , Holman, R. R. and Lopes, R. D. (2017) International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: insights from the NAVIGATOR Trial. Journal of the American Heart Association, 6(1), e003892. (doi: 10.1161/JAHA.116.003892) (PMID:28087508) (PMCID:PMC5523624)

Mc Causland, F. R. et al. (2017) Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: data from the trial to reduce cardiovascular events with aranesp therapy trial. American Journal of Nephrology, 46(6), pp. 488-497. (doi: 10.1159/000485326) (PMID:29241199)

Miro, Ò. et al. (2017) European Society of Cardiology - Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department. European Heart Journal: Acute Cardiovascular Care, 6(4), pp. 311-320. (doi: 10.1177/2048872616633853) (PMID:26900163)

Pitts, R. et al. (2017) Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure. Journal of the American Heart Association, 6(1), e004119. (doi: 10.1161/JAHA.116.004119) (PMID:28073769) (PMCID:PMC5523625)

Ridker, P. M. et al. (2017) Cardiovascular efficacy and safety of Bococizumab in high-risk patients. New England Journal of Medicine, 376(16), pp. 1527-1539. (doi: 10.1056/NEJMoa1701488) (PMID:28304242)

2016

Khder, Y., Shi, V., McMurray, J. J.V. and Lefkowitz, M. P. (2016) Sacubitril/valsartan (LCZ696) in heart failure. In: Handbook of Experimental Pharmacology. Springer. (doi: 10.1007/164_2016_77)

Teerlink, J. R. et al. (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, 388(10062), pp. 2895-2903. (doi: 10.1016/S0140-6736(16)32049-9)

Zile, M. R. et al. (2016) Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. Journal of the American College of Cardiology, 68(22), pp. 2425-2436. (doi: 10.1016/j.jacc.2016.09.931) (PMID:27908347)

Damman, K., Solomon, S. D., Pfeffer, M. A., Swedberg, K., Yusuf, S., Young, J. B., Rouleau, J. L., Granger, C. B. and McMurray, J. J.V. (2016) Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure, 18(12), pp. 1508-1517. (doi: 10.1002/ejhf.609) (PMID:27427441)

Mc Causland, F. R. et al. (2016) C-Reactive protein and risk of ESRD: results from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 68(6), pp. 873-881. (doi: 10.1053/j.ajkd.2016.07.022) (PMID:27646425) (PMCID:PMC5123931)

Pitts, R. et al. (2016) Treatment with Dalcetrapib modifies the relationship between high-density lipoprotein cholesterol and C-reactive protein. Journal of the American College of Cardiology, 68(22), pp. 2488-2490. (doi: 10.1016/j.jacc.2016.09.932) (PMID:27908356)

Ponikowski, P. et al. (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica]. Revista Española de Cardiología, 69(12), 1167.e1-1167.e85. (doi: 10.1016/j.recesp.2016.10.014)

Ferreira, J. P. et al. (2016) Renal function estimation and Cockroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: the Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 14, 181. (doi: 10.1186/s12916-016-0731-2) (PMID:27829460) (PMCID:PMC5103492)

Pfeffer, M. A. and McMurray, J. J.V. (2016) Lessons in uncertainty and humility — Clinical trials involving hypertension. New England Journal of Medicine, 375(18), pp. 1756-1766. (doi: 10.1056/NEJMra1510067) (PMID:27806228)

Martín-Sánchez, F. J. et al. (2016) Practical approach on frail older patients attended for acute heart failure. International Journal of Cardiology, 222, pp. 62-71. (doi: 10.1016/j.ijcard.2016.07.151) (PMID:27458825)

Kirchhof, P. et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 18(11), pp. 1609-1678. (doi: 10.1093/europace/euw295) (PMID:27567465)

Savarese, G., Giugliano, R. P., Rosano, G. M.C., McMurray, J. , Magnani, G., Filippatos, G., Dellegrottaglie, S., Lund, L. H., Trimarco, B. and Perrone-Filardi, P. (2016) Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC: Heart Failure, 4(11), pp. 881-884. (doi: 10.1016/j.jchf.2016.07.012) (PMID:27614940)

Rørth, R. et al. (2016) Return to the workforce following first hospitalization for heart failure: a Danish nationwide cohort study. Circulation, 134(14), pp. 999-1009. (doi: 10.1161/CIRCULATIONAHA.116.021859) (PMID:27507406)

Cotter, G. et al. (2016) Predictors and associations with outcomes of length of hospital stay in patients with acute heart failure: results from VERITAS. Journal of Cardiac Failure, 22(10), pp. 815-822. (doi: 10.1016/j.cardfail.2015.12.017) (PMID:26721775)

Solomon, S. D., Claggett, B., McMurray, J. J.V. , Hernandez, A. F. and Fonarow, G. C. (2016) Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. European Journal of Heart Failure, 18(10), pp. 1238-1243. (doi: 10.1002/ejhf.603) (PMID:27364182)

Solomon, S. D., Claggett, B., Packer, M., Desai, A., Zile, M. R., Swedberg, K., Rouleau, J., Shi, V., Lefkowitz, M. and McMurray, J. J.V. (2016) Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC: Heart Failure, 4(10), pp. 816-822. (doi: 10.1016/j.jchf.2016.05.002) (PMID:27395349)

Vardeny, O. et al. (2016) Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure, 18(10), pp. 1228-1234. (doi: 10.1002/ejhf.580) (PMID:27283779) (PMCID:PMC5095784)

McMurray, J. J.V. (2016) The ICD in heart failure - time for a rethink? New England Journal of Medicine, 375(13), pp. 1283-1284. (doi: 10.1056/NEJMe1609826) (PMID:27571386)

Judge, P.K. et al. (2016) Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data. Nephrology Dialysis Transplantation, (doi: 10.1093/ndt/gfw321) (PMID:27646835)

McMurray, J. J.V. (2016) Site selection and performance in clinical trials. Circulation: Heart Failure, 9(9), e003490. (doi: 10.1161/CIRCHEARTFAILURE.116.003490) (PMID:27623771)

Chin, K. L. et al. (2016) Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. European Journal of Heart Failure, 18(9), pp. 1175-1181. (doi: 10.1002/ejhf.485) (PMID:26833642)

Gaziano, T. A., Fonarow, G. C., Claggett, B., Chan, W. W., Deschaseaux-Voinet, C., Turner, S. J., Rouleau, J. L., Zile, M. R., McMurray, J. J.V. and Solomon, S. D. (2016) Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiology, 1(6), pp. 666-672. (doi: 10.1001/jamacardio.2016.1747) (PMID:27438344)

Hawkins, N. M. et al. (2016) Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. European Journal of Heart Failure, 18(9), pp. 1162-1171. (doi: 10.1002/ejhf.614) (PMID:27594177)

Jhund, P. S. and McMurray, J. J.V. (2016) The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 102(17), pp. 1342-1347. (doi: 10.1136/heartjnl-2014-306775) (PMID:27207980) (PMCID:PMC5013095)

Okumura, N. et al. (2016) Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. Circulation: Heart Failure, 9(9), e003212. (doi: 10.1161/CIRCHEARTFAILURE.116.003212) (PMID:27618854)

Senni, M. et al. (2016) Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. European Journal of Heart Failure, 18(9), pp. 1193-1202. (doi: 10.1002/ejhf.548) (PMID:27170530) (PMCID:PMC5084812)

McMurray, J. J.V. , Dickstein, K. and Kober, L. V. (2016) The author's reply - Aliskiren, Enalapril, or both in heart failure. New England Journal of Medicine, 375(7), pp. 701-702. (doi: 10.1056/NEJMc1606625) (PMID:27532843)

Hawkins, N. M., Virani, S. A., Sperrin, M., Buchan, I. E., McMurray, J. J.V. and Krahn, A. D. (2016) Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges. European Journal of Heart Failure, 18(8), pp. 977-986. (doi: 10.1002/ejhf.458) (PMID:26663507)

Cannon, J. A., Shen, L., Jhund, P. , Anand, I. S., Komajda, M., McKelvie, R. S., Zile, M. R., Carson, P. E. and McMurray, J. J. V. (2016) Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-Preserve) trial. European Journal of Heart Failure, 18(8), pp. 1021-1031. (doi: 10.1002/ejhf.547) (PMID:27194023)

Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 18(8), pp. 891-975. (doi: 10.1002/ejhf.592) (PMID:27207191)

Desai, A. S. et al. (2016) Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. Journal of the American College of Cardiology, 68(3), pp. 241-248. (doi: 10.1016/j.jacc.2016.04.047) (PMID:27417000)

McMurray, J. J.V. and Køber, L. V. (2016) End of the road for vagus nerve stimulation? Journal of the American College of Cardiology, 68(2), pp. 159-160. (doi: 10.1016/j.jacc.2016.05.025) (PMID:27386768)

Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J.V. (2016) SGLT2 and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1333-1339. (doi: 10.1007/s00125-016-3956-x) (PMID:27112340) (PMCID:PMC4901113)

Sattar, N. , McLaren, J., Kristensen, S. L., Preiss, D. and McMurray, J. J. (2016) Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 59(7), pp. 1573-1574. (doi: 10.1007/s00125-016-3987-3) (PMID:27174369) (PMCID:PMC4969788)

Okumura, N. et al. (2016) Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation, 133(23), pp. 2254-2262. (doi: 10.1161/CIRCULATIONAHA.115.020729) (PMID:27143684)

Woodcock, J., Ware, J. H., Miller, P. W., McMurray, J. J.V. , Harrington, D. P. and Drazen, J. M. (2016) Clinical Trials Series. New England Journal of Medicine, 374(22), p. 2167. (doi: 10.1056/NEJMe1601510)

Berry, C. et al. (2016) Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. QJM: An International Journal of Medicine, 109(6), pp. 377-382. (doi: 10.1093/qjmed/hcv087) (PMID:25979270)

Metra, M. et al. (2016) Geographic differences in patients in a global acute heart failure clinical trial (from the ASCEND-HF Trial). American Journal of Cardiology, 117(11), pp. 1771-1778. (doi: 10.1016/j.amjcard.2016.03.002) (PMID:27108685)

Abdul-Rahim, A. H. et al. (2016) Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal, 1(2), pp. 93-100. (doi: 10.1177/2396987316646025)

Anker, S. D. et al. (2016) Erratum to “Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency” [Eur J Heart Fail 2016;18:482-489]. European Journal of Heart Failure, 18(6), p. 727. (doi: 10.1002/ejhf.591) (PMID:27324688)

Desai, A. S., Solomon, S., Claggett, B., McMurray, J. J.V. , Rouleau, J., Swedberg, K., Zile, M., Lefkowitz, M., Shi, V. and Packer, M. (2016) Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF trial. Circulation: Heart Failure, 9(6), e002735. (doi: 10.1161/CIRCHEARTFAILURE.115.002735) (PMID:27296397)

Lopes, R. D., Pieper, K. S., Stevens, S. R., Solomon, S. D., McMurray, J. J.V. , Pfeffer, M. A., Leimberger, J. D. and Velazquez, E. J. (2016) Predicting outcomes over time in patients with heart failure, left ventricular systolic dysfunction, or both following acute myocardial infarction. Journal of the American Heart Association, 5(6), e003045. (doi: 10.1161/JAHA.115.003045) (PMID:27353607) (PMCID:PMC4937254)

Whellan, D. J., Stebbins, A., Hernandez, A. F., Ezekowitz, J. A., McMurray, J. J.V. , Mather, P. J., Hasselblad, V. and O'Connor, C. M. (2016) Dichotomous relationship between age and 30-day death or rehospitalization in heart failure patients admitted with acute decompensated heart failure: results from the ASCEND-HF trial. Journal of Cardiac Failure, 22(6), pp. 409-416. (doi: 10.1016/j.cardfail.2016.02.011) (PMID:26952241)

McMurray, J. J.V. (2016) Disease management programs in cardiology. Circulation, 133(19), pp. 1836-1837. (doi: 10.1161/circulationaha.116.022480) (PMID:27083508)

Anker, S. D. et al. (2016) Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 18(5), pp. 482-489. (doi: 10.1002/ejhf.516) (PMID:27071916)

Campbell, R. T., Willox, G. P., Jhund, P. S. , Hawkins, N. M., Huang, F., Petrie, M. C. and McMurray, J. J. V. (2016) Reporting of lost to follow-up and treatment discontinuation in device and pharmacotherapy trials in chronic heart failure: a systematic review. Circulation: Heart Failure, 9(5), e002842. (doi: 10.1161/CIRCHEARTFAILURE.115.002842) (PMID:27162229)

McMurray, J. J.V. et al. (2016) Aliskiren, enalapril, or aliskiren and enalapril in heart failure. New England Journal of Medicine, 374(16), pp. 1521-1532. (doi: 10.1056/NEJMoa1514859) (PMID:27043774)

Abdul-Rahim, A. H. , MacIsaac, R. L., Jhund, P. S. , Petrie, M. C. , Lees, K. R. and McMurray, J. J.V. (2016) Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology, 209, pp. 310-316. (doi: 10.1016/j.ijcard.2016.02.074) (PMID:26913372)

Heerspink, H. J.L. et al. (2016) Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes and Endocrinology, 4(4), pp. 309-317. (doi: 10.1016/S2213-8587(15)00469-6) (PMID:26774608)

McMurray, J. J.V. and Køber, L. (2016) Trials and the ‘real world’ - how different are they? European Journal of Heart Failure, 18(4), pp. 411-413. (doi: 10.1002/ejhf.503) (PMID:27019978)

Sabe, M. A. et al. (2016) Coronary artery disease is a predictor of progression to dialysis in patients with chronic kidney disease, type 2 diabetes mellitus, and anemia: an analysis of the trial to reduce cardiovascular events with aranesp therapy (TREAT). Journal of the American Heart Association, 5(4), e002850. (doi: 10.1161/JAHA.115.002850) (PMID:27108247) (PMCID:PMC4859277)

Samsky, M. D. et al. (2016) Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. European Journal of Heart Failure, 18(4), pp. 424-432. (doi: 10.1002/ejhf.440) (PMID:26707029)

Teerlink, J. R. et al. (2016) Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure. Journal of the American College of Cardiology, 67(12), pp. 1444-1455. (doi: 10.1016/j.jacc.2016.01.031) (PMID:27012405)

Ambrosy, A. P. et al. (2016) The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 18(3), pp. 306-313. (doi: 10.1002/ejhf.420) (PMID:26467269)

Damman, K., Kjekshus, J., Wikstrand, J., Cleland, J. G.F. , Komajda, M., Wedel, H., Waagstein, F. and McMurray, J. J.V. (2016) Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 18(3), pp. 328-336. (doi: 10.1002/ejhf.462) (PMID:26693947)

Perez, A. L. et al. (2016) Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. European Journal of Heart Failure, 18(3), pp. 290-297. (doi: 10.1002/ejhf.456) (PMID:26663359)

Solomon, S. D. et al. (2016) Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (lcz696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circulation: Heart Failure, 9(3), e002744. (doi: 10.1161/CIRCHEARTFAILURE.115.002744) (PMID:26915374)

Heerspink, H.J.L. et al. (2016) Is a reduction in albuminuria associated with renal and cardiovascular protection? A post-hoc analysis of the ALTITUDE trial. Diabetes, Obesity and Metabolism, 18(2), pp. 169-177. (doi: 10.1111/dom.12600) (PMID:26511599)

Vardeny, O. et al. (2016) Influenza vaccination in patients with chronic heart failure: The PARADIGM-HF Trial. JACC: Heart Failure, 4(2), pp. 152-158. (doi: 10.1016/j.jchf.2015.10.012) (PMID:26746371)

Kristensen, S. L. et al. (2016) Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circulation: Heart Failure, 9(1), e002560. (doi: 10.1161/CIRCHEARTFAILURE.115.002560) (PMID:26754626) (PMCID:PMC4718182)

McMurray, J. (2016) EMPA-REG – the “diuretic hypothesis”. Journal of Diabetes and its Complications, 30(1), pp. 3-4. (doi: 10.1016/j.jdiacomp.2015.10.012) (PMID:26597600)

Tang, W.H. W. et al. (2016) Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure. JACC: Heart Failure, 4(1), pp. 68-77. (doi: 10.1016/j.jchf.2015.07.015) (PMID:26656144)

Theilade, S., Claggett, B., Hansen, T.W., Skali, H., Lewis, E.F., Solomon, S.D., Parving, H.-H., Pfeffer, M., McMurray, J.J. and Rossing, P. (2016) Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia-the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Journal of Human Hypertension, 30(1), pp. 46-52. (doi: 10.1038/jhh.2015.22) (PMID:25810068)

Zile, M. R. et al. (2016) Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction. Circulation: Heart Failure, 9(1), e002551. (doi: 10.1161/circheartfailure.115.002551) (PMID:26754625)

Emdin, C. A. et al. (2016) Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. Heart, 103(1), pp. 55-62. (doi: 10.1136/heartjnl-2016-309706) (PMID:27530132)

Jackson, C. E. et al. (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 18(12), pp. 1491-1498. (doi: 10.1002/ejhf.543) (PMID:27114189)

Kirchhof, P. et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery, 50(5), e1-e88. (doi: 10.1093/ejcts/ezw313) (PMID:27663299)

Kirchhof, P. et al. (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 37(38), pp. 2893-2962. (doi: 10.1093/eurheartj/ehw210) (PMID:27567408)

Kristensen, S. L. et al. (2016) Geographic variations in the PARADIGM-HF heart failure trial. European Heart Journal, 37(41), pp. 3167-3174. (doi: 10.1093/eurheartj/ehw226) (PMID:27354044) (PMCID:PMC5106574)

Nadruz, W. et al. (2016) Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial). Circulation, 134(22), pp. 1785-1787. (doi: 10.1161/CIRCULATIONAHA.116.024976) (PMID:27895026)

Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), pp. 2129-2200. (doi: 10.1093/eurheartj/ehw128) (PMID:27206819)

2015

Cannon, J. A., McKean, A. R., Jhund, P. S. and McMurray, J. J.V. (2015) What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? Open Heart, 2(1), e000283. (doi: 10.1136/openhrt-2015-000283) (PMID:26719808) (PMCID:PMC4692046)

Pocock, S. J., McMurray, J. J.V. and Collier, T. J. (2015) Statistical controversies in reporting of clinical trials: part 2 of a 4-part series on statistics for clinical trials. Journal of the American College of Cardiology, 66(23), pp. 2648-62. (doi: 10.1016/j.jacc.2015.10.023) (PMID:26670066)

Pocock, S. J., McMurray, J. J.V. and Collier, T. J. (2015) Making sense of statistics in clinical trial reports: Part 1 of a 4-part series on statistics for clinical trials. Journal of the American College of Cardiology, 66(22), pp. 2536-2549. (doi: 10.1016/j.jacc.2015.10.014) (PMID:26653629)

Claggett, B., Packer, M., McMurray, J. J.V. , Swedberg, K., Rouleau, J., Zile, M. R., Jhund, P., Lefkowitz, M., Shi, V. and Solomon, S. D. (2015) Estimating the long-term treatment benefits of Sacubitril–Valsartan. New England Journal of Medicine, 373(23), pp. 2289-2290. (doi: 10.1056/NEJMc1509753) (PMID:26630151)

Gheorghiade, M. et al. (2015) Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction. JAMA: Journal of the American Medical Association, 314(21), pp. 2251-2262. (doi: 10.1001/jama.2015.15734) (PMID:26547357)

McMurray, J. J.J.V. (2015) Improving outcomes in heart failure: a personal perspective. European Heart Journal, 36(48), pp. 3467-3470. (doi: 10.1093/eurheartj/ehv565) (PMID:26578200)

Pfeffer, M. A. et al. (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine, 373(23), pp. 2247-2257. (doi: 10.1056/NEJMoa1509225) (PMID:26630143)

Simpson, J. et al. (2015) Comparing LCZ696 with Enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores. Journal of the American College of Cardiology, 66(19), pp. 2059-2071. (doi: 10.1016/j.jacc.2015.08.878) (PMID:26541915)

McMurray, J.J. et al. (2015) A new cost-effectiveness modelling approach in chronic heart failure with reduced ejection fraction - PCV118. Value in Health, 18(7), A394. (doi: 10.1016/j.jval.2015.09.887) (PMID:26532224)

Wang, N. et al. (2015) Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. European Heart Journal, (doi: 10.1093/eurheartj/ehv558) (PMID:26530103)

Bello, N. A. et al. (2015) Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. European Journal of Heart Failure, 17(11), pp. 1201-1207. (doi: 10.1002/ejhf.412) (PMID:26423928) (PMCID:PMC4703474)

Simpson, J. et al. (2015) Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. European Journal of Heart Failure, 17(11), pp. 1182-1191. (doi: 10.1002/ejhf.346) (PMID:26358762)

Jhund, P. et al. (2015) Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 36(38), pp. 2576-2584. (doi: 10.1093/eurheartj/ehv330) (PMID:26231885) (PMCID:PMC4595742)

Grodin, J. L. et al. (2015) Circulating kidney injury molecule-1 levels in acute heart failure. JACC: Heart Failure, 3(10), pp. 777-785. (doi: 10.1016/j.jchf.2015.06.006) (PMID:26449997)

Krum, H. et al. (2015) The Aliskiren trial to minimize outcomes in patients with heart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics. European Journal of Heart Failure, 17(10), pp. 1075-1083. (doi: 10.1002/ejhf.408) (PMID:26511146)

Jhund, P. et al. (2015) Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal, 36(36), pp. 2463-2469. (doi: 10.1093/eurheartj/ehv295) (PMID:26188211)

Girerd, N., Collier, T., Pocock, S., Krum, H., McMurray, J. J. , Swedberg, K., Van Veldhuisen, D. J., Vincent, J., Pitt, B. and Zannad, F. (2015) Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. European Heart Journal, 36(34), pp. 2310-2317. (doi: 10.1093/eurheartj/ehv273) (PMID:26093641)

Charytan, D. M. et al. (2015) Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT). American Journal of Kidney Diseases, 66(3), pp. 429-440. (doi: 10.1053/j.ajkd.2015.02.324) (PMID:25935581)

Fisher, M., Petrie, M. , Ambery, P., Donaldson, J., McMurray, J. J.V. and Ye, J. (2015) Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes and Endocrinology, 3(9), pp. 697-703. (doi: 10.1016/s2213-8587(15)00233-8) (PMID:26276240)

Kao, D. P., Lewsey, J. D. , Anand, I. S., Massie, B. M., Zile, M. R., Carson, P. E., McKelvie, R. S., Komajda, M., McMurray, J. J.V. and Lindenfeld, J. (2015) Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure, 17(9), pp. 925-935. (doi: 10.1002/ejhf.327) (PMID:26250359)

Platz, E., Jhund, P. S. , Campbell, R. T. and McMurray, J. (2015) Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. European Journal of Heart Failure, 17(9), pp. 906-916. (doi: 10.1002/ejhf.321) (PMID:26230356) (PMCID:PMC4725064)

McMurray, J. J.V. (2015) It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD? European Heart Journal, 36(31), pp. 2047-2049. (doi: 10.1093/eurheartj/ehv190) (PMID:25994745)

Desai, A. S. et al. (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal, 36(30), pp. 1990-1997. (doi: 10.1093/eurheartj/ehv186) (PMID:26022006)

Mebazaa, A. et al. (2015) Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. European Heart Journal, 36(30), pp. 1958-1966. (doi: 10.1093/eurheartj/ehv066) (PMID:25998514)

Askevold, E. T., Gullestad, L., Nymo, S., Kjekshus, J., Yndestad, A., Latini, R., Cleland, J. G.F. , McMurray, J. J.V. , Aukrust, P. and Ueland, T. (2015) Secreted frizzled related protein 3 in chronic heart failure: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). PLoS ONE, 10(8), e0133970. (doi: 10.1371/journal.pone.0133970) (PMID:26288364) (PMCID:PMC4545831)

Jackson, C. E. et al. (2015) Combined free light chains are novel predictors of prognosis in heart failure. JACC: Heart Failure, 3(8), pp. 618-625. (doi: 10.1016/j.jchf.2015.03.014) (PMID:26251088)

Jhund, P. S. , Anand, I. S., Komajda, M., Claggett, B. L., McKelvie, R. S., Zile, M. R., Carson, P. E. and McMurray, J. J.V. (2015) Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. European Journal of Heart Failure, 17(8), pp. 809-817. (doi: 10.1002/ejhf.274) (PMID:25921853)

Khazanie, P. et al. (2015) Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated heart failure outcome models. American Heart Journal, 170(2), pp. 290-297. (doi: 10.1016/j.ahj.2015.04.006) (PMID:26299226)

Lewis, E. F. et al. (2015) Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. American Heart Journal, 170(2), 322-329.e4. (doi: 10.1016/j.ahj.2015.05.008) (PMID:26299230)

Preiss, D. et al. (2015) Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 5(8), e007901. (doi: 10.1136/bmjopen-2015-007901) (PMID:26275900) (PMCID:PMC4550730)

Rush, C. J., Campbell, R. T., Jhund, P. S. , Connolly, E. C., Preiss, D. , Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC: Heart Failure, 3(8), pp. 603-614. (doi: 10.1016/j.jchf.2015.03.013) (PMID:26251086)

Yates, T. et al. (2015) Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. Diabetic Medicine, 32(8), pp. 1090-1096. (doi: 10.1111/dme.12762) (PMID:25818859)

Emdin, C. A., Callender, T., Cao, J., McMurray, J. J.V. and Rahimi, K. (2015) Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure. American Journal of Cardiology, 116(1), pp. 155-61. (doi: 10.1016/j.amjcard.2015.03.052) (PMID:25937349)

Cannon, J.A. et al. (2015) Clinical outcomes according to QRS duration and morphology in the eplerenone in mild patients: hospitalization and survIval study in heart failure (EMPHASIS-HF). European Journal of Heart Failure, 17(7), pp. 707-716. (doi: 10.1002/ejhf.303) (PMID:26139584)

Green, J. B. et al. (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 373(3), pp. 232-242. (doi: 10.1056/NEJMoa1501352) (PMID:26052984)

Harinstein, M. E. et al. (2015) Site selection for heart failure clinical trials in the USA. Heart Failure Reviews, 20(4), pp. 375-383. (doi: 10.1007/s10741-015-9473-z) (PMID:25649127)

Dalzell, J. R., Rocchiccioli, J. P., Weir, R. A.P., Jackson, C. E., Padmanabhan, N., Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) The emerging potential of the apelin-APJ system in heart failure. Journal of Cardiac Failure, 21(6), pp. 489-498. (doi: 10.1016/j.cardfail.2015.03.007) (PMID:25795508)

Kristensen, S. L., Jhund, P. S. , Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., Komajda, M., Cleland, J. G.F. , Carson, P. E. and McMurray, J. J.V. (2015) Relative importance of history of heart failure hospitalization and N-terminal pro–B-type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 3(6), pp. 478-486. (doi: 10.1016/j.jchf.2015.01.014) (PMID:26046842)

Mebazaa, A. et al. (2015) Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergenc. European Journal of Heart Failure, 17(6), pp. 544-558. (doi: 10.1002/ejhf.289) (PMID:25999021)

Preiss, D. et al. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36(24), pp. 1536-1546. (doi: 10.1093/eurheartj/ehv072) (PMID:25802390) (PMCID:PMC4769322)

Bentley-Lewis, R. et al. (2015) Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 169(5), 631-638.e7. (doi: 10.1016/j.ahj.2015.02.002) (PMID:25965710)

Abdul-Rahim, A. H. et al. (2015) Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the controlled rosuvastatin in multinational trial heart failure (corona) and the gruppo italiano per lo studio della sopravvivenza nell'insufficienza cardiaca-heart failure (gissi-hf) trials. Circulation, 131(17), pp. 1486-1494. (doi: 10.1161/CIRCULATIONAHA.114.013760) (PMID:25810334)

Ezekowitz, J. A. et al. (2015) Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. European Heart Journal: Cardiovascular Pharmacotherapy, 1(2), pp. 86-94. (doi: 10.1093/ehjcvp/pvu024) (PMID:27533976)

Feinstein, M. J., Jhund, P. , Kang, J., Ning, H., Maggioni, A., Wikstrand, J., Kjekshus, J., Tavazzi, L., McMurray, J. and Lloyd-Jones, D. M. (2015) Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. European Journal of Heart Failure, 17(4), pp. 434-441. (doi: 10.1002/ejhf.247) (PMID:25684642)

Vazir, A. et al. (2015) Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal, 36(11), pp. 669-675. (doi: 10.1093/eurheartj/ehu401) (PMID:25368202)

Campbell, R. T. et al. (2015) Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. ESC Heart Failure, 2(1), pp. 25-36. (doi: 10.1002/ehf2.12027) (PMID:27347426) (PMCID:PMC4864752)

DeVore, A. D. et al. (2015) Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. European Journal of Heart Failure, 17(3), pp. 340-346. (doi: 10.1002/ejhf.235) (PMID:25619549)

Haver, V. G. et al. (2015) Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA). European Journal of Heart Failure, 17(3), pp. 313-9. (doi: 10.1002/ejhf.237) (PMID:25639660)

Katz, M., Califf, R. M., Sun, J.-L., McMurray, J. J.V. , Thomas, L. and Lopes, R. D. (2015) Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. American Journal of Medicine, 128(3), pp. 297-302. (doi: 10.1016/j.amjmed.2014.08.022) (PMID:25447626)

Metra, M. et al. (2015) Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. Journal of Cardiac Failure, 21(3), pp. 179-88. (doi: 10.1016/j.cardfail.2014.12.012) (PMID:25573829)

Badar, A. A. et al. (2015) Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) programme. European Journal of Heart Failure, 17(2), pp. 196-204. (doi: 10.1002/ejhf.221)

Hijazi, Z. et al. (2015) Comparison of cardiac troponins i and t measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clinical Chemistry, 61(2), pp. 368-378. (doi: 10.1373/clinchem.2014.226936) (PMID:25451868)

Kristensen, S. L. et al. (2015) Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 17(2), pp. 169-176. (doi: 10.1002/ejhf.211) (PMID:25756844)

Ueland, T., Aukrust, P., Nymo, S. H., Kjekshus, J., McMurray, J. J.V. , Wikstrand, J., Block, D., Zaugg, C. and Gullestad, L. (2015) Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial. Journal of Cardiac Failure, 21(2), pp. 153-9. (doi: 10.1016/j.cardfail.2014.10.016) (PMID:25451704)

Abdul-Rahim, A.H. , Fulton, R.L., Frank, B., McMurray, J.J.V. and Lees, K.R. (2015) Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. European Journal of Neurology, 22(1), pp. 163-169. (doi: 10.1111/ene.12548) (PMID:25370204)

Kristensen, S. L. L. et al. (2015) International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation, 131(1), pp. 43-53. (doi: 10.1161/CIRCULATIONAHA.114.012284)

Packer, M. et al. (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation, 131(1), pp. 54-61. (doi: 10.1161/circulationaha.114.013748) (PMID:25403646) (PMCID:25403646)

Swerdlow, D. I. et al. (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, 385(9965), pp. 351-361. (doi: 10.1016/S0140-6736(14)61183-1) (PMID:25262344) (PMCID:PMC4322187)

Tang, W.H. W. et al. (2015) Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. JACC: Heart Failure, 3(1), pp. 40-9. (doi: 10.1016/j.jchf.2014.06.014) (PMID:25453534)

Ueland, T., Aukrust, P., Nymo, S. H., Kjekshus, J., McMurray, J. J.V. , Wikstrand, J., Wienhues-Thelen, U.-H., Block, D., Zaugg, C. and Gullestad, L. (2015) Predictive value of endostatin in chronic heart failure patients with poor kidney function. Cardiology, 130(1), pp. 17-22. (doi: 10.1159/000368220) (PMID:25428583)

Abdul-Rahim, A. H. et al. (2015) Response to Letter Regarding Article, “Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.”. Circulation, 132(22), e358. (doi: 10.1161/CIRCULATIONAHA.115.018395) (PMID:26621661)

Abualnaja, S., Podder, M., Hernandez, A. F., McMurray, J. J. V. , Starling, R. C., O'Connor, C. M., Califf, R. M., Armstrong, P. W. and Ezekowitz, J. A. (2015) Acute heart failure and atrial fibrillation: insights from the acute study of clinical effectiveness of nesiritide in decompensated heart failure (ASCEND‐HF) trial. Journal of the American Heart Association, 4(8), e002092. (doi: 10.1161/JAHA.115.002092) (PMID:26304935) (PMCID:PMC4599466)

Badar, A. A. et al. (2015) Clinical characteristics and outcomes of patients with coronary artery disease and angina. Circulation: Heart Failure, 8(4), pp. 717-724. (doi: 10.1161/CIRCHEARTFAILURE.114.002024) (PMID:26067854)

Cannon, J. A., McMurray, J. J.V. and Quinn, T. J. (2015) ‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure. Alzheimer's Research and Therapy, 7, 22. (doi: 10.1186/s13195-015-0106-5) (PMID:25722749) (PMCID:PMC4342092)

Carson, P. E. et al. (2015) The hospitalization burden and post-hospitalization mortality risk in heart failure with preserved ejection fraction: results from the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). JACC: Heart Failure, 3(6), pp. 429-441. (doi: 10.1016/j.jchf.2014.12.017) (PMID:25982110)

Jackson, C. E. et al. (2015) Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. European Heart Journal, 36(18), pp. 1106-14. (doi: 10.1093/eurheartj/ehu490) (PMID:25616644)

Lam, C. S. P. et al. (2015) Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the valsartan in acute myocardial infarction trial (VALIANT). European Journal of Heart Failure, 17(3), pp. 301-312. (doi: 10.1002/ejhf.238) (PMID:25655011)

Lewsey, J. et al. (2015) Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 15(3), (doi: 10.1186/s12883-014-0257-1) (PMID:25591718) (PMCID:PMC4320501)

McMurray, J. , Zhu, L., McKillop, I. and Chen, H. (2015) Modelling system level health information exchange: an ontological approach. Studies in Health Technology and Informatics, 208, pp. 269-274. (PMID:25676986)

McMurray, J. (2015) Ethnic-specific normative reference values for echocardiographic LA and LV size, LV mass, and systolic function: the EchoNoRMAL Study. JACC: Cardiovascular Imaging, 8(6), pp. 656-665. (doi: 10.1016/j.jcmg.2015.02.014) (PMID:25981507)

McMurray, J. J.V. (2015) Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. European Journal of Heart Failure, 17(3), pp. 242-7. (doi: 10.1002/ejhf.250) (PMID:25756942)

Roberts, E., Ludman, A. J., Dworzynski, K., Al-Mohammad, A., Cowie, M. R., McMurray, J. J. V. and Mant, J. (2015) The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. British Medical Journal, 350, h910. (doi: 10.1136/bmj.h910) (PMID:25740799) (PMCID:PMC4353288)

Voors, A. A. et al. (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 17(5), pp. 510-517. (doi: 10.1002/ejhf.232) (PMID:25657064)

2014

Badar, A. A. et al. (2014) Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 35(48), pp. 3426-3433. (doi: 10.1093/eurheartj/ehu342)

Damman, K., Tang, W. H. W., Testani, J. M. and McMurray, J. J. V. (2014) Terminology and definition of changes renal function in heart failure. European Heart Journal, 35(48), pp. 3413-3416. (doi: 10.1093/eurheartj/ehu320) (PMID:25157110)

Das, D., Bakal, J. A., Westerhout, C. M., Hernandez, A. F., O'Connor, C. M., Atar, D., McMurray, J. J.V. , Armstrong, P. W. and Ezekowitz, J. A. (2014) The association between meteorological events and acute heart failure: new insights from ASCEND-HF. International Journal of Cardiology, 177(3), pp. 819-824. (doi: 10.1016/j.ijcard.2014.11.066) (PMID:25465826)

van Diepen, S. et al. (2014) Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. International Journal of Cardiology, 177(3), pp. 840-846. (doi: 10.1016/j.ijcard.2014.11.007) (PMID:25465830)

McMurray, J. J.V. , Packer, M. and Solomon, S. D. (2014) Neprilysin inhibition for heart failure. New England Journal of Medicine, 371(24), pp. 2336-2337. (doi: 10.1056/NEJMc1412654) (PMID:25494275)

Campbell, R. T., McKean, A. R. and McMurray, J. J.V. (2014) Acute heart failure: have we got it all wrong? European Journal of Heart Failure, 16(12), pp. 1263-1267. (doi: 10.1002/ejhf.197)

Chin, M. P. et al. (2014) Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Journal of Cardiac Failure, 20(12), pp. 953-958. (doi: 10.1016/j.cardfail.2014.10.001) (PMID:25307295)

Cotter, G. et al. (2014) Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. European Journal of Heart Failure, 16(12), pp. 1362-1371. (doi: 10.1002/ejhf.186) (PMID:25371147)

McMurray, J. J.V. and van Veldhuisen, D. J. (2014) β blockers, atrial fibrillation, and heart failure. Lancet, 384(9961), pp. 2181-2183. (doi: 10.1016/S0140-6736(14)62340-0) (PMID:25625384)

Preiss, D. et al. (2014) Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 16(12), pp. 1265-1268. (doi: 10.1111/dom.12320) (PMID:24861892)

Cannon, J. A. and McMurray, J. J.V. (2014) Gut feelings about heart failure. Journal of the American College of Cardiology, 64(18), pp. 1915-1916. (doi: 10.1016/j.jacc.2014.04.088)

Adabag, S., Rector, T. S., Anand, I. S., McMurray, J. J. , Zile, M., Komajda, M., McKelvie, R. S., Massie, B. and Carson, P. E. (2014) A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 16(11), pp. 1175-1182. (doi: 10.1002/ejhf.172)

Desai, A. S. et al. (2014) Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation: Heart Failure, 7(6), pp. 895-902. (doi: 10.1161/CIRCHEARTFAILURE.114.001567)

Lee, D., Wilson, K., Akehurst, R., Cowie, M.R., Zannad, F., Krum, H., van Veldhuisen, D.J., Vincent, J., Pitt, B. and McMurray, J.J.V. (2014) Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart, 100(21), pp. 1681-1687. (doi: 10.1136/heartjnl-2014-305673) (PMID:24993605) (PMCID:PMC4215293)

Oluleye, O. W., Rector, T. S., Win, S., McMurray, J. J. V. , Zile, M. R., Komajda, M., McKelvie, R. S., Massie, B., Carson, P. E. and Anand, I. S. (2014) History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulation: Heart Failure, 7(6), pp. 960-966. (doi: 10.1161/CIRCHEARTFAILURE.114.001523)

Patel, P. A. et al. (2014) Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. Circulation: Heart Failure, 7(6), pp. 918-925. (doi: 10.1161/CIRCHEARTFAILURE.113.000872)

Preiss, D. , McMurray, J. J. and Sattar, N. (2014) Treatment of severe hypertriglyceridaemia. Lancet Diabetes and Endocrinology, 2(11), p. 860. (doi: 10.1016/s2213-8587(14)70052-x) (PMID:25439459)

de Barros e Silva, P. G.M., Califf, R. M., Sun, J.-L., McMurray, J. J.V. , Holman, R., Haffner, S., Thomas, L. and Lopes, R. D. (2014) Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. International Journal of Cardiology, 176(3), pp. 1126-1128. (doi: 10.1016/j.ijcard.2014.07.297) (PMID:25220176)

Wong, C.M. et al. (2014) Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 35(39), pp. 2714-2721. (doi: 10.1093/eurheartj/ehu216)

Dworzynski, K., Roberts, E., Ludman, A., Mant, J. and McMurray, J. (2014) Diagnosing and managing acute heart failure in adults: summary of NICE guidance. British Medical Journal, 349, g5695-g5695. (doi: 10.1136/bmj.g5695) (PMID:25296764)

Shah, A. M. et al. (2014) Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF? Journal of the American College of Cardiology, 64(14), pp. 1535-1536. (doi: 10.1016/j.jacc.2014.04.084) (PMID:25277624)

McMurray, J. J.V. , Gerstein, H. C., Holman, R. R. and Pfeffer, M. A. (2014) Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes and Endocrinology, 2(10), pp. 843-851. (doi: 10.1016/S2213-8587(14)70031-2)

Rahimi, K., Bennett, D., Conrad, N., Williams, T. M., Basu, J., Dwight, J., Woodward, M., Patel, A., McMurray, J. and MacMahon, S. (2014) Risk prediction in patients with heart failure. JACC: Heart Failure, 2(5), pp. 440-446. (doi: 10.1016/j.jchf.2014.04.008) (PMID:25194291)

Santos, A. B.S. et al. (2014) Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 16(10), pp. 1096-1103. (doi: 10.1002/ejhf.147) (PMID:25138249)

Damman, K., Perez, A. C., Anand, I. S., Komajda, M., McKelvie, R. S., Zile, M. R., Massie, B., Carson, P. E. and McMurray, J. J.V. (2014) Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology, 64(11), pp. 1106-1113. (doi: 10.1016/j.jacc.2014.01.087)

Jessup, M., Fox, K. A.A., Komajda, M., McMurray, J. J.V. and Packer, M. (2014) PARADIGM-HF — The experts' discussion. New England Journal of Medicine, 371(11), e15. (doi: 10.1056/NEJMp1410203) (PMID:25184757)

McMurray, J. J.V. et al. (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), pp. 993-1004. (doi: 10.1056/NEJMoa1409077) (PMID:25176015)

van Deursen, V.M. et al. (2014) Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the acute study of clinical effectiveness of nesiritide and decompensated heart failure (ASCEND-HF). Circulation, 130(12), pp. 958-965. (doi: 10.1161/CIRCULATIONAHA.113.003046) (PMID:25074507)

Callender, T. et al. (2014) Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Medicine, 11(8), e1001699. (doi: 10.1371/journal.pmed.1001699) (PMID:25117081) (PMCID:PMC4130667)

Jennings, C. G. et al. (2014) Up-titration of allopurinol in patients with gout. Seminars in Arthritis and Rheumatism, 44(1), pp. 25-30. (doi: 10.1016/j.semarthrit.2014.01.004)

Padwal, R. et al. (2014) The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. International Journal of Obesity, 38(8), pp. 1110-1114. (doi: 10.1038/ijo.2013.203) (PMID:24173404)

Bello, N. A., Claggett, B., Desai, A. S., McMurray, J. J. V. , Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A. and Solomon, S. D. (2014) Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation: Heart Failure, 7(4), pp. 590-595. (doi: 10.1161/CIRCHEARTFAILURE.113.001281)

Böhm, M. et al. (2014) Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure, 16(7), pp. 778-787. (doi: 10.1002/ejhf.85)

Campbell, R. T. and McMurray, J. J.V. (2014) Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. Heart Failure Clinics, 10(3), pp. 481-501. (doi: 10.1016/j.hfc.2014.04.009)

Holman, R. R. et al. (2014) Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal, 168(1), 23-29.e2. (doi: 10.1016/j.ahj.2014.03.021)

McMurray, J. J.V. et al. (2014) Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). European Journal of Heart Failure, 16(7), pp. 817-825. (doi: 10.1002/ejhf.115) (PMID:24828035) (PMCID:PMC4312884)

Jhund, P. S. et al. (2014) Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. European Journal of Heart Failure, 16(6), pp. 671-677. (doi: 10.1002/ejhf.76)

Rogers, J. K. et al. (2014) Effect of rosuvastatin on repeat heart failure hospitalizations: The CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure, 2(3), pp. 289-297. (doi: 10.1016/j.jchf.2013.12.007)

Gori, M. et al. (2014) Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 16(5), pp. 535-542. (doi: 10.1002/ejhf.67) (PMID:24574260)

Kalogeropoulos, A. P. et al. (2014) High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. Journal of Cardiac Failure, 20(5), pp. 319-326. (doi: 10.1016/j.cardfail.2014.02.002) (PMID:24530944)

Rogers, J. K., Pocock, S. J., McMurray, J. J.V. , Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K. and Yusuf, S. (2014) Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved’ [Eur J Heart Fail2014;16:33-40]. European Journal of Heart Failure, 16(5), p. 592. (doi: 10.1002/ejhf.86)

Sliwa, K. et al. (2014) EURObservational research programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. European Journal of Heart Failure, 16(5), pp. 583-591. (doi: 10.1002/ejhf.68)

Bello, N. A. et al. (2014) Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Research and Care, 2(1), e000011. (doi: 10.1136/bmjdrc-2013-000011) (PMID:25452859) (PMCID:PMC4212578)

Butler, J. et al. (2014) Developing therapies for heart failure with preserved ejection fraction. JACC: Heart Failure, 2(2), pp. 97-112. (doi: 10.1016/j.jchf.2013.10.006) (PMID:24720916) (PMCID:PMC4028447)

Huffman, K. M. et al. (2014) Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. Metabolism, 63(4), pp. 554-561. (doi: 10.1016/j.metabol.2014.01.002) (PMID:24559843) (PMCID:PMC4103164)

McMurray, J. J.V. and O'Connor, C. (2014) Lessons from the TOPCAT trial. New England Journal of Medicine, 370(15), pp. 1453-1454. (doi: 10.1056/NEJMe1401231) (PMID:24716685)

Perez-Moreno, A. C. et al. (2014) Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure, 2(2), pp. 187-197. (doi: 10.1016/j.jchf.2014.01.001) (PMID:24720928)

Damman, K., Tang, W.H. W., Felker, G. M., Lassus, J., Zannad, F., Krum, H. and McMurray, J. J.V. (2014) Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency. Journal of the American College of Cardiology, 63(9), pp. 853-871. (doi: 10.1016/j.jacc.2013.11.031) (PMID:24334210)

Doughty, R. N. et al. (2014) A meta-analysis of echocardiographic measurements of the left heart for the development of normative reference ranges in a large international cohort: the EchoNoRMAL study. European Heart Journal: Cardiovascular Imaging, 15(3), pp. 341-348. (doi: 10.1093/ehjci/jet240) (PMID:24247924)

Moukarbel, G. V., Yu, Z.-F., Dickstein, K., Hou, Y. R., Wittes, J. T., McMurray, J. J.V. , Pitt, B., Zannad, F., Pfeffer, M. A. and Solomon, S. D. (2014) The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. European Journal of Heart Failure, 16(3), pp. 289-299. (doi: 10.1002/ejhf.11) (PMID:24464979)

Yates, T. et al. (2014) Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet, 383(9922), pp. 1059-1066. (doi: 10.1016/s0140-6736(13)62061-9) (PMID:24361242)

Hijazi, Z. et al. (2014) High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation, 129(6), pp. 625-634. (doi: 10.1161/CIRCULATIONAHA.113.006286) (PMID:24226808)

Kraigher-Krainer, E. et al. (2014) Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 63(5), pp. 447-456. (doi: 10.1016/j.jacc.2013.09.052) (PMID:24184245)

Preiss, D. , Lloyd, S. M. , Ford, I. , McMurray, J. J.V. , Holman, R. R., Welsh, P. , Fisher, M., Packard, C. J. and Sattar, N. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, 2(2), pp. 116-124. (doi: 10.1016/S2213-8587(13)70152-9) (PMID:24622715)

Dalzell, J. R., Seed, A., Berry, C. , Whelan, C. J., Petrie, M. C. , Padmanabhan, N., Clarke, A., Biggerstaff, F., Hillier, C. and McMurray, J. J.V. (2014) Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovascular Therapeutics, 32(1), pp. 13-18. (doi: 10.1111/1755-5922.12053) (PMID:24138103)

Perez, A. C., Jhund, P. S. , Stott, D. J. , Gullestad, L., Cleland, J. G.F. , van Veldhuisen, D. J., Wikstrand, J., Kjekshus, J. and McMurray, J. J.V. (2014) Thyroid-stimulating hormone and clinical outcomes. JACC: Heart Failure, 2(1), pp. 35-40. (doi: 10.1016/j.jchf.2013.07.008)

Wikstrand, J., Wedel, H., Castagno, D. and McMurray, J.J.V. (2014) The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. Journal of Internal Medicine, 275(2), pp. 134-143. (doi: 10.1111/joim.12141) (PMID:24118421)

Alexander, J. H. et al. (2014) Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, 35(4), pp. 224-232. (doi: 10.1093/eurheartj/eht445) (PMID:24144788)

Damman, K. and McMurray, J. J.V. (2014) Why and when should we worry about worsening renal function? European Journal of Heart Failure, 16(1), pp. 4-5. (doi: 10.1111/ejhf.17) (PMID:24453094)

Gravning, J., Askevold, E.T., Nymo, S.H., Ueland, T., Wikstrand, J., McMurray, J.J.V. , Aukrust, P., Gullestad, L. and Kjekshus, J. (2014) Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circulation: Heart Failure, 7(1), pp. 96-103. (doi: 10.1161/CIRCHEARTFAILURE.113.000450) (PMID:24284025)

Hijazi, Z. et al. (2014) High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. Journal of the American College of Cardiology, 63(1), pp. 52-61. (doi: 10.1016/j.jacc.2013.07.093) (PMID:24055845)

Jackson, C. E., Myles, R. C. and McMurray, J. J.V. (2014) Microvolt T-wave alternans testing in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 16(1), p. 113. (doi: 10.1111/ejhf.45) (PMID:24453101)

Nymo, S. H., Hulthe, J., Ueland, T., McMurray, J. , Wikstrand, J., Askevold, E. T., Yndestad, A., Gullestad, L. and Aukrust, P. (2014) Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome: results from CORONA. European Journal of Heart Failure, 16(1), pp. 68-75. (doi: 10.1093/eurjhf/hft125) (PMID:23918775)

Rogers, J. K., Pocock, S. J., McMurray, J. J.V. , Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K. and Yusuf, S. (2014) Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-preserved. European Journal of Heart Failure, 16(1), pp. 33-40. (doi: 10.1002/ejhf.29) (PMID:24453096)

Calvo, G. et al. (2014) Large streamlined trials in cardiovascular disease. European Heart Journal, 35(9), pp. 544-548. (doi: 10.1093/eurheartj/eht535)

Clark, B., DuChane, J., Hou, J., Rubenstein, E., McMurray, J. and Duncan, I. (2014) Evaluation of increased adherence and cost savings of an employer value-based benefits program targeting generic antihyperlipidemic and antidiabetic medications. Journal of Managed Care Pharmacy, 20(2), pp. 141-150. (PMID:24456315)

Eschalier, R. et al. (2014) Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function. analyses of the emphasis-hf study subgroups (eplerenone in mild patients hospitalization and survival study in heart failure). Rational Pharmacotherapy in Cardiology, 10(1), pp. 106-115. (doi: 10.20996/1819-6446-2014-10-1-106-115)

Gori, M. et al. (2014) Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal, 35(48), pp. 3442-3451. (doi: 10.1093/eurheartj/ehu254) (PMID:24980489)

Hood, Jr., W. B., Dans, A. L., Guyatt, G. H., Jaeschke, R. and McMurray, J. J. (2014) Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database of Systematic Reviews, 2014(4), CD002901. (doi: 10.1002/14651858.CD002901.pub3)

Jhund, P.S. et al. (2014) Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor lcz696. Circulation: Heart Failure, 7(6), pp. 953-959. (doi: 10.1161/CIRCHEARTFAILURE.114.001427)

Kraigher-Krainer, E. et al. (2014) Erratum: Impaired systolic function by strain imaging in heart failure with preserved ejection fraction ( Journal of the American College of Cardiology (2014) 63 (447-456)). Journal of the American College of Cardiology, 64(3), p. 335. (doi: 10.1016/j.jacc.2014.06.011)

MacDonald, T. M. et al. (2014) Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open, 4(7), e005354. (doi: 10.1136/bmjopen-2014-005354)

McMurray, J. et al. (2014) A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 36(7), pp. 434-439. (doi: 10.1093/eurheartj/ehu455) (PMID:25416329) (PMCID:PMC4328198)

Rossignol, P. et al. (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). Circulation: Heart Failure, 7(1), pp. 51-58. (doi: 10.1161/CIRCHEARTFAILURE.113.000792) (PMID:24297687)

Santos, A.B.S. et al. (2014) Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. European Heart Journal, 35(1), pp. 42-47. (doi: 10.1093/eurheartj/eht427) (PMID:24164863)

Wallentin, L. et al. (2014) Response to letter regarding article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation". Circulation, 129(2), e21-e22. (doi: 10.1161/CIRCULATIONAHA.113.005709)

2013

de Zeeuw, D. et al. (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. New England Journal of Medicine, 369(26), pp. 2492-2503. (doi: 10.1056/NEJMoa1306033) (PMID:24206459)

Krum, H., Massie, B., Abraham, W. T., Dickstein, K., Kober, L. and McMurray, J. J.V. (2013) Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. European Journal of Heart Failure, 15(11), pp. 1205-1207. (doi: 10.1093/eurjhf/hft133) (PMID:23989432)

Lambers Heerspink, H.J. et al. (2013) Baseline characteristics in the bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrology Dialysis Transplantation, 28(11), pp. 2841-2850. (doi: 10.1093/ndt/gft445) (PMID:24169612)

Latini, R. et al. (2013) Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors: a post hoc analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. American Heart Journal, 166(5), 935-940.e1. (doi: 10.1016/j.ahj.2013.08.012) (PMID:24176451)

Wong, C.M. et al. (2013) Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme. Journal of the American College of Cardiology, 62(20), pp. 1845-1854. (doi: 10.1016/j.jacc.2013.05.072)

Yancy, C. W. et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Journal of the American College of Cardiology, 62(16), pp. 1495-1539. (doi: 10.1016/j.jacc.2013.05.020) (PMID:23741057)

Yancy, C. W. et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.